Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Buzz

Evaluate and EP Vantage Mentioned in the Press or Industry Reports

October 2016

 

Look Back at Pharma News to Sept. 2 – The Pharma Letter, September 4, 2016

“.... with its sole asset, APL-130277, approaching the finish line, it was rewarded with a $624 million takeover by Japan's Sumitomo Dainippon, noted EP Vantage...”

 

September 2016

 

Look Back at Pharma News to Sept. 2 – The Pharma Letter, September 4, 2016

“.... with its sole asset, APL-130277, approaching the finish line, it was rewarded with a $624 million takeover by Japan's Sumitomo Dainippon, noted EP Vantage...”

 

Прогноз на стабильность и активность крупных фармкомпаний на мировом рынке  – PharmNews.kz, September 5, 2016

“Аналитическая компания Evaluate Pharma прогнозирует стабильность фармацевтических компаний в 2016 г. Укреплению их позиций на мировом рынке будет способствовать большое количество R&D-новинок, которые могут достичь статуса блокбастеров через 5 лет после лонча…”

 

Astra And Lexicon Provide The Good News In Diabetes  – Seeking Alpha, September 6, 2016

“Boehringer Ingelheim and Lilly’s (NYSE:LLY) top seller, Jardiance, has seen its 2020 forecast nearly double, from $1.6bn to $3bn, in the past 12 months - source EvaluatePharma...”

 

Astra Could Be Fashionably Late With Benralizumab  – Seeking Alpha, September 6, 2016

“Nucala’s 2022 sales forecast is more than double that for benralizumab, according to EvaluatePharma sell-side consensus (see table below)...”

 

3 Stocks to Help Fund Your Retirement  – Pantagraph, September 7, 2016

“EvaluatePharma, for instance, is already forecasting a staggering $11 billion in Opdivo sales by 2021....”

 

Array Plays the Cardiovascular Card  – Seeking Alpha, September 7, 2016

“Array originated as a research company focused on kinases, building drugs for important biological targets that either had no drugs or didn’t have good drugs. Because that was our focus we were somewhat agnostic to therapeutic area,” he tells EP Vantage...”

 

U.S. Deals Dominate Medtech M&A  – Seeking Alpha, September 7, 2016

“A recent EP Vantage analysis revealed that, in the biopharma world, European companies are splashing the cash on US-based takeovers, while a lot less is spent in the other direction...”

 

Immodulon Rises From The Ashes Of SR Pharma  – Seeking Alpha, September 8, 2016

“That's why we're sticking to philanthropic money,” Immodulon's chairman, Dr Charles Akle, tells EP Vantage. He has raised £35m ($47m), mainly from private...”

 

Look Back at Pharma News to Sept. 9  – Seeking Alpha, September 11, 2016

“...to the party again with its anti-interleukin-5 antibody benralizumab, with the project nearly two years behind GlaxoSmithKline's Nucala, noted EP Vantage, ...”

 

Рекорды остались позади: итоги І полугодия 2016 г. для мировой фармацевтической отрасли  – Apteka, September 12, 2016

“Поскольку Хиллари Клинтон в одной из социальных сетей сообщала о том, что собирается заняться этим вопросом, победа демократов, вероятно, будет означать больше проблем для фармацевтической отрасли США, считают аналитики компании «Evaluate Pharma»…”

 

GSK, Janssen submit sirukumab in Europe, planning for 2016 FDA filing – FierceBiotech, September 13, 2016

“The treatment has long been pegged as a blockbuster in waiting, with 2020 sales predicted to hit $1.8 billion, according to analyst estimates compiled by EvaluatePharma...”

 

Google's Diabetes Partnerships Could Be Just The Start  – Seeking Alpha, September 13, 2016

“It is therefore no surprise that five of the 16 technology crossover deals tracked by EP Vantage are in diabetes.....”

 

Horizon Pharma forks out $800 million to acquire Raptor  – The Pharma Letter, September 13, 2016

“Commenting on the deal, EP Vantage, the editorial arm of the Evaluate group, stated: “Big pharma is desperate to buy to restock its pipelines, but not all biotechs are Medivation....”

 

Worldwide Prescription Drug Sales Forecast to Grow 6.3 Percent Annually  – Yahoo! Finance, September 14, 2016

“However, for those willing to take a longer-term view, the outlook is more nuanced, with a projected compound annual growth rate of 6.3 percent in global prescription sales over the next six years according to the EvaluatePharma World Preview 2016, Outlook to 2022 report from life science market intelligence firm, Evaluate Ltd...”

 

Worldwide Prescription Drug Sales Forecast to Grow 6.3 Percent Annually  – PharmiWeb, September 14, 2016

“However, for those willing to take a longer-term view, the outlook is more nuanced, with a projected compound annual growth rate of 6.3 percent in global prescription sales over the next six years according to the EvaluatePharma World Preview 2016, Outlook to 2022 report from life science market intelligence firm, Evaluate Ltd...”

 

Allergan to Buy Vitae Pharmaceuticals for $639 Million  – Wall Street Journal, September 14, 2016

“Such treatments make up one of the drug industry’s biggest markets, which EvaluatePharma says had nearly $49 billion in world-wide sales last year...”

 

Teva's Transformation Reveals A Generics Market In Turmoil  – Seeking Alpha, September 14, 2016

“But an analysis of sellside forecasts, compiled by EvaluatePharma, illustrates how tough this will be: the Teva and Actavis generics businesses combined are set to grow at around 4% over the next five years...”

 

With Sepsis Trial Done, InflaRx Turns To Heart Surgery  – Seeking Alpha, September 14, 2016

“Whenever you hear the word sepsis, people are scared away, people don’t want to fund programs, and people know it’s a big market but they know everyone fails,” chief executive Niels Riedemann tells EP Vantage...”

 

Astra Still Hopes for Brilliance with Brilinta  – Seeking Alpha, September 15, 2016

“Deutsche Bank analysts estimate that unapproved indications could make up $750m of Brilinta’s 2022 revenues, a fair-sized chunk of EvaluatePharma’s current $2.1bn consensus forecast...”

 

Biosimilars won't stop Enbrel, Humira from growing through 2022: Analyst  – FiercePharma, September 15, 2016

“EvaluatePharma's new World Preview report pegs 2022 sales for Humira only slightly below Porges' estimates--at $13.6 billion--and Enbrel higher, at $7.2 billion...”

 

Roche to beat Novartis, Pfizer to pharma throne by 2022 as industry passes $1T mark  – FiercePharma, September 15, 2016

“EvaluatePharma sees Roche's pipeline as the most valuable in the industry, although the Basel-based pharma's strategy comes with risk...”

 

Worldwide prescription drug sales forecast to grow 6.3% – Manufacturing Chemist Pharma, September 15, 2016

“Global prescription sales are forecast to rise at a compound annual growth rate (CAGR) of 6.3% over the next six years, according to the EvaluatePharma World Preview 2016, Outlook to 2022 report from life science market intelligence firm, Evaluate…”

 

Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data  – Seeking Alpha, September 16, 2016

“According to consensus forecasts from EvaluatePharma, Humira sales will peak in 2018 at $18.6bn, falling back to $13.8bn by 2022, while ABP 501 is forecast to reach $810m that year...”

 

Novavax is down 80%. Here’s why it’s been really hard to develop an RSV vaccine  – CNBC, September 16, 2016

“Yet, as EP Vantage's Jacob Plieth pointed out, Glenn said in May "this RSV season has remained consistent with previous years."...”

 

Roche станет глобальным лидером по объему продаж к 2022 г.  – SK Pharmacy, September 16, 2016

“Швейцарские фармацевтические компании Novartis и Roche соперничают друг с другом в борьбе за мировое лидерство по объему продаж рецептурных лекарственных средств до 2022 г., сообщает FiercePharma со ссылкой на отчет World Preview, подготовленный аналитической компанией Evaluate Pharma…”

 

Farmaci, la previsione: nel mondo +6,3% prescrizioni fino al 2022  – MeteoWeb, September 16, 2016

“La società EvaluatePharma azzarda una previsione di aumento delle prescrizioni di medicinali del 6,3% a un tasso composto di crescita annuo (Cagr) nei prossimi 6 anni…”

 

Evaluate prognostiziert eine Billion Dollar weltweite Rx-Umsätze  – Healthcare Marketing, September 16, 2016

“Das Londoner Marktforschungsunternehmen Evaluate prognostiziert ein jährliches Wachstum der weltweiten Rx-Umsätze von 6,3 Prozent bis zum Jahr 2022…”

 

Novavax shares wiped after PhIII RSV vaccine failure  – FiercePharma, September 16, 2016

“Just this week, the program was pegged as a top 5 vax R&D project worldwide by value from EvaluatePharma analysts, who predicted $846 million in 2022 sales for the vaccine...”

 

Global pharma market forecast to reach $1.12tr by 2022  – PMLive, September 16, 2016

“EvaluatePharma expects new products to drive this growth, with the upward trajectory of approvals for new molecular entities (NMEs) that saw 50 NMEs approved in 2014 and 56 in 2015 showing little sign of slowing down...”

 

Pharmaceutiques: Roche futur leader devant Novartis et Pfizer ?  – Francais Express, September 16, 2016

“Actuellement numéro 3 de l'industrie pharmaceutique, Roche deviendra le leader du secteur pharmaceutique en terme de chiffre d'affaires dans les années à venir,selon un scénario établi par le cabinet de conseil Evaluate Pharma...”

 

Las ventas mundiales en prescripción crecerán un 6,3% anual hasta 2022  – Diariofarma, September 16, 2016

“Las ventas mundiales de medicamentos de prescripción crecerán a un ritmo del 6,3% interanual en el periodo 2016-2022, según las estimaciones recogidas en el informe 'World Preview 2016, Outlook 2022' de la consultora especializada EvaluatePharma...”

 

Pharmaceutiques : Roche futur leader devant Novartis et Pfizer?  – La Tribune, September 16, 2016

“Roche génèrera près de 53 milliards de dollars de revenus en 2022, selon une étude d'Evaluate Pharma...”

 

Roche станет глобальным лидером по объему продаж к 2022 г.  – Фармацевтический вестник, September 16, 2016

“Швейцарские фармацевтические компании Novartis и Roche соперничают друг с другом в борьбе за мировое лидерство по объему продаж рецептурных лекарственных средств до 2022 г., сообщает FiercePharma со ссылкой на отчет World Preview, подготовленный аналитической компанией Evaluate Pharma...”

 

Novartis/Amgen migraine drug shows promise  – Pharmaphorum, September 16, 2016

“EP Vantage expects Erenumab to bring in sales of almost half a billion in 2022 if approved, although a rival migraine drug being developed by Teva could bring in sales north of a billion by that time…”

 

Look back at news to Sept 16  – The Pharma Letter, September 18, 2016

“EP Vantage, the editorial arm of the Evaluate group, comments that Google’s latest venture – the diabetes collaboration with Sanofi now known as Onduo – is another example of tech companies getting involved in the healthcare world…”

 

Amgen-UCB bone drug cuts fractures in osteoporosis for older women  – FierceBiotech, September 19, 2016

“ Meanwhile, abaloparatide could bring in $467 million by 2022, according to EvaluatePharma sell-side consensus...”

 

Ecco le stime di Evaluate per i prossimi anni: Novartis superata da Roche  – Goinpharma, September 19, 2016

“L’azienda di consulenza e ricerche di mercato Evaluate Research ha oggi pubblicato il suo e EvaluatePharma World Preview 2016...”

 

Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says  – STAT, September 19, 2016

“The average annual cost per patient for such medications rose to $112,000 from $84,000 between 2010 and 2014, according to EvaluatePharma, a research firm...”

 

Novartis says MS drug siponimod reduces the risk of disability progression  – The Pharma Letter, September 19, 2016

“Siponimod could figure more prominently in Novartis’s outlook after release of data from the Phase III Expand trial in secondary progressive multiple sclerosis, according to EP Vantage, the editorial arm of the Evaluate group...”

 

The Puzzling Excuse For Novavax's Pivotal Failure  – Seeking Alpha, September 19, 2016

“Asked by EP Vantage about the differing views of the severity of the season, which runs during the winter months, the company said it was aware of what analysts wrote, but its “only statement about attack rate ... was made as part of yesterday’s call”...”

 

Amgen-UCB bone drug cuts fractures in osteoporosis for older women  – Wessex Life Sciences, September 19, 2016

“Meanwhile, abaloparatide could bring in $467 million by 2022, according to EvaluatePharma sell-side consensus. ..”

 

Roche se dit bien armé pour faire face à la concurrence des biosimilaires  – L’usine Nouvelle, September 20, 2016

“Le scénario que vient de publier le cabinet d’études Evaluate Pharma estime que Roche sera le leader mondial du secteur en 2022 avec un chiffre d’affaires de 52,6 milliards de dollars (47 milliards d'euros), devant Novartis et Pfizer…”

 

Vendite farmaci: nel 2022 sarà testa a testa Roche-Novartis  – Multipla Sclerosi News, September 20, 2016

“Secondo il nuovo rapporto di EvaluatePharma, Roche dovrebbe ottenere 52,6 miliardi di dollari nel 2022 dalla vendita dei farmaci da prescrizione, con un’espansione prevista quindi del…”

 

Biontech Deal Sees Roche Bet On mRNA  – Seeking Alpha, September 22, 2016

“This is a highly competitive area,” he told EP Vantage. “Since we published our original Nature paper we’ve noticed a number of companies have announced they’re entering this area, so we want to keep that confidential” ...”

 

Bubble Stocks Top The Takeover Premium Charts – Seeking Alpha, September 23, 2016

“This is according to EvaluatePharma data, which until now ranked Roche’s (OTCQX:RHHBY) buyout of Anadys as the frothiest since 2011, at a 256% premium...”

 

Look Back at Pharma News to Sept 23  – The Pharma Letter, September 25, 2016

“The Phase III failure of Danish CNS specialist Lundbeck’s idalopirdine is yet another example of just how difficult Alzheimer’s drug development is, and another nail in the coffin for the 5-HT6 antagonist class, says EP Vantage, the editorial arm of the Evaluate group...”

 

What Happens To Pharma’s Incredible Ride On The ‘Gravy Train’?  – Pilman, September 26, 2016

“For example, according to ‘Evaluate Pharma World Preview 2016, Outlook to 2022’ report, the overall R&D pipeline value of Roche is US$ 43.2 billion, far ahead of the same of Novartis’ US$ 24.1 billion and AstraZeneca’s at US$ 23.2 billion, followed by Eli Lilly, AbbVie, Pfizer, Sanofi, Celgene, Biogen and J&J and in that order…”

 

 

Landstingens dilemma - priset på ett liv  – Sveriges Radio, September 26, 2016

(radio transcript of interview with LisaUrquhart) “- Hello. Oh my name is Lisa Urquhart. I am editor of EP Vantage, which is a part of EvaluatePharma…”

 

Revved up by Novartis swap, GSK expected to top Sanofi, Pfizer and Merck in 2022 vax sales – FiercePharma, September 27, 2016

“EvaluatePharma predicts Pfizer and Merck vaccines sales to grow 2% each year through 2022, below an industry average of 5%. In 2022, Pfizer's vaccines are expected to bring in $7.4 billion and Merck's, $7.2 billion...”

 

Las ventas mundiales de medicamentos con receta crecerán a un ritmo del 6,3% anual – Imfarmacias, September 28, 2016

“EvaluatePharma presenta la última edición de su Informe Mundial sobre la industria farmacéutica…”

 

Pfizer's Prevnar 13 sales set for decline as patient pool shrinks, report says  – Wessex Life Sciences, September 28, 2016

“EvaluatePharma (EP) projects that Pfizer Inc. (NYSE:PFE) is looking at an annual sales decline of 1% in the next five years for Prevnar 13, its bacterial pneumonia vaccine....”

 

Foamix Spots Dermatology Opportunity  – Seeking Alpha, September 29, 2016

“The Israeli company Foamix Pharmaceuticals (NASDAQ:FOMX) believes that it has a solution with FMX101, a foam version of the antibiotic minocycline that is due to report phase III results next year. “We haven’t seen any drug-related systemic side effects in any of our studies,” its chief executive, Dov Tamarkin, tells EP Vantage.....”

 

Why Teva and Regeneron Entered Collaboration Agreement  – Market Realist, September 29, 2016

“EvaluatePharma’s analysts expect Fasinumab to fetch $105 million in 2022, while the deal suggests peak sales potential of $500 million...”

 

Incyte pads positive early data for cancer combo – BioPharmaDIVE, September 29, 2016

“The clinical and market successes of Mercky's Keytruda and Bristol-Myers Squibb' Opdivo (nivolumab) have spurred nearly 100 combination studies pairing the PD-1 inhibitors with various other small-molecule drugs, immuno-oncology agents or vaccines, according to a report from EP Vantage...”

 

Incyte pads positive early data for cancer combo – BioPharmaDIVE, September 29, 2016

“The clinical and market successes of Mercky's Keytruda and Bristol-Myers Squibb' Opdivo (nivolumab) have spurred nearly 100 combination studies pairing the PD-1 inhibitors with various other small-molecule drugs, immuno-oncology agents or vaccines, according to a report from EP Vantage...”

 

Diabetes Care Market Is Expected to See Fast Growth  – Market Realist, September 30, 2016

“According to EvaluatePharma, the global diabetes care market is expected to grow at a compounded average growth rate of about 6% to 7% from 2014 to 2020, while the overall pharmaceutical industry is estimated to grow at a CAGR of 4% in the same time period....”

 

Cлияния и поглощения фармкомпаний на мировом рынке – Pharmapractice.eu, September Issue, 2016

“Аналитики Evaluate Pharma показывают, что M&A-активность фармацевтических и биотехнологических компаний за І полугодие 2016 г…”

 

К 2022 Году Roche Вырвется В Лидеры По Объему Продаж – PharmNews.kz, September Issue, 2016

“Швейцарские фармацевтические компании Roche и Novartis соперничают друг с другом в борьбе за мировое лидерство по объему продаж рецептурных лекарственных средств до 2022 года. Об этом говорится в отчете World Preview, который был подготовлен аналитической компанией Evaluate Pharma…”

 

 August 2016

 

ACTIVE BIOTECH COMPANY SHARES IN THE NEWS: EPIRUS BIOPHARMACEUTICALS, INC. (NASDAQ:EPRS), SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) – Voice Registrar, August 1, 2016

"The projected innovator or class sales for these products are estimated at almost $6 billion in global sales in 2020, according to EvaluatePharma®…"

 

Sanofi/Regeneron eye 2017 EU approval for Humira-beater sarilumab  – FierceBiotech, August 1, 2016

"The treatment has been touted as a blockbuster in waiting, with 2020 sales predicted to hit $1.8 billion, according to analyst estimates compiled by EvaluatePharma…"

 

Data From RNAi In Hep B And A Novel Dermatitis Antibody  – Seeking Alpha, August 1, 2016

"According to consensus from EvaluatePharma, ARB-1467 sales are expected to reach $155m by 2022, which would make it the fifth biggest hep B drug that year (see table). Arrowhead’s ARC-520, another RNAi therapeutic, takes the third spot. ARC-520 is intended to disrupt production of hep B proteins necessary for the virus to replicate and is in a number of phase II trials…"

 

BIOTECH STOCKS WORTH A CLOSER LOOK: HEAT BIOLOGICS, INC. (NASDAQ:HTBX), EPIRUS BIOPHARMACEUTICALS, INC. (NASDAQ:EPRS)  – Voice Registrar, August 2, 2016

"The Company’s current pipeline of biosimilar product candidates includes: BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); and additional undisclosed assets. The projected innovator or class sales for these products are estimated at almost $6 billion in global sales in 2020, according to EvaluatePharma®…"

 

Pfizer's Ibrance on pace for blockbuster status after strong Q2  – BioPharmaDIVE, August 2, 2016

"However, even if the FDA approves Novartis' ribociclib later this year, an analysis by Evaluate Pharma concludes Ibrance will stay in the lead given its pole position on the market, forecasting $5.3 billion in global sales by 2022..."

 

Ionis Endears Itself To Investors - And To Biogen  – Seeking Alpha, August 2, 2016

"If the data are good enough for approval the orphan nature of SMA – there are around 15,000 patients in the US – means the companies can charge top dollar. EvaluatePharma’s consensus forecasts 2022 sales of $742m but analysts at Evercore ISI put risk-adjusted peak sales at $1.7bn by 2025, based on a price of $250,000 per year and a median one-year duration of therapy. Leerink analysts are even more bullish, putting peak sales at $2.1bn by 2022…"

 

GSK Victory a Shot in the Arm for HPV Vaccine  – Caixin Online, August 2, 2016

"Currently, Cervarix and Gardasil, which is produced by Merck & Co., are the only globally available products for HPV immunization. Combined sales of these drugs topped US$ 2 billion last year, according to pharmaceutical industry information provider Evaluate Pharma…"

 

Big Pharma benefits more from breakthrough therapy designations: report  – BioPharmaDIVE, August 2, 2016

“Since breakthrough therapy designations were introduced in 2012, large pharma companies have benefited more than other companies, according to a new report from EP Vantage… But the EP Vantage report suggests big pharma companies have a significant advantage both in procuring BTDs and receiving expedited approval through the process…”

 

Big Pharma Tightens Its Grip On Breakthrough Designations  – Seeking Alpha, August 2, 2016

"If this is one clear trend, another has emerged more slowly: breakthrough therapy designations (BTDs) are accruing mainly to big pharma. And now an analysis by EvaluatePharma links the two, showing how reduced review times have also largely favored big pharma over smaller groups with BTDs under their belts (see tables below)…"

 

TRADING THE BIOTECH NEWS: EXELIXIS, INC. (NASDAQ:EXEL), EPIRUS BIOPHARMACEUTICALS, INC. (NASDAQ:EPRS)  – Voice Registrar, August 3, 2016

"The Company’s current pipeline of biosimilar product candidates includes: BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); and additional undisclosed assets. The projected innovator or class sales for these products are estimated at almost $6 billion in global sales in 2020, according to EvaluatePharma®…"

 

AstraZeneca Might Have Created Value But Now It Needs To Deliver  – Seeking Alpha, August 3, 2016

"A look at how sell-side analysts view the company’s pipeline suggests that many agree AstraZeneca has indeed created substantial value – $24.4bn in NPV terms over the last three years, according to an analysis of EvaluatePharma data – a record that ranks them favorably among their big pharma peers (see table below). Whether that makes them vulnerable to another bid approach is another matter entirely…"

 

Takeover rumors juice Biogen stock, but fade fast – BioPharmaDIVE, August 3, 2016

“Consensus sales forecasts put 2022 revenue at $4.7 billion, according to EP Vantage—much lower than previous bullish estimates which ranged from $6 billion to as much as $9 billion. And chief financial officer Paul Clancy recently indicated Biogen halted its direct-to-consumer marketing campaign for the drug, acknowledging it failed to increase prescriptions…”

 

Carmat's Heart Approaches Market As Rival Hits The Buffers  – Seeking Alpha, August 3, 2016

“Carmat seeks to treat patients even more desperately ill. They have extremely severe heart failure and a life expectancy of less than two weeks, Mr Conviti tells EP Vantage…”

 

INTRADAY ACTIVE BIOTECH STOCKS NEWS: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (NASDAQ:PACB), EPIRUS BIOPHARMACEUTICALS, INC. (NASDAQ:EPRS)  – Voice Registrar, August 4, 2016

"The Company’s current pipeline of biosimilar product candidates includes: BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); and additional undisclosed assets. The projected innovator or class sales for these products are estimated at almost $6 billion in global sales in 2020, according to EvaluatePharma®…"

 

Il boom dei cari farmaci orfani  – TorinoMedica, August 4, 2016

"Secondo il Rapporto di EvaluatePharma, nel 2014 il costo medio di un medicinale orfano ha raggiunto i 112.000 dollari all’anno per paziente per anno, contro i 23.000 dollari degli altri farmaci…"

 

Biosimilars Emerge As Winners In Annual Payer Muscle Flexing  – Seeking Alpha, August 4, 2016

"According to EvaluatePharma’s archived forecasts, consensus for Basaglar has been creeping up over the past few years, jumping 31% to $825m for 2020 over the last 12 months alone. The product remains decidedly in launch phase, having only reached the market in Europe mid-2015. It sold $16m in the second quarter of this year, but the long-term view is arguably still conservative…"

 

Finding the cure: rare diseases  – Investors Chronicle UK, August 5, 2016

"According to industry analysts Evaluate Pharma there are 566 medicines in development for patients with rare diseases and of these 151 are for cancers, with 82 specifically for blood cancer…"

 

Despite trial restart, Juno pushes back launch timeline for CAR-T therapy – BioPharmaDIVE, August 5, 2016

“Kite Pharma now looks set to be the first to file, eyeing this year for a submission to the FDA and an approval sometime in 2017, according to EP Vantage. Novartis appears more conservative and plans to file sometime in 2017 for its CTL-019 therapy…”

 

Big Pharma's R&D Zero-To-Hero Story – Seeking Alpha, August 5, 2016

“Analysts now believe that this cohort’s R&D assets are worth a combined $225bn, representing growth of 53% since EP Vantage last did this analysis two years ago, and more than double in three years (see tables below)… AstraZeneca (NYSE:AZN) is a standout in this analysis, as the net present value of its R&D pipeline is equal to 35% of its market cap, up from 22% in EP Vantage’s 2014 analysis…”

 

Merck's Keytruda wins a double-header with new FDA approval in head-and-neck cancer  – FiercePharma, August 8, 2016

"First approved in 2014, both Keytruda and Opdivo are forecast by EvaluatePharma to be among the top 20 best-selling drugs in the world by 2020. The pharma research firm believes Opdivo could reach $8.4 billion in annual sales by 2020 sales while it forecasts Keytruda achieving $4.5 billion in annual sales…"

 

Schizophrenia And Tinnitus Data From Intra-Cellular And Auris  – Seeking Alpha, August 8, 2016

"ITI-007 is Intra-cellular’s lead asset, and is also in trials for bipolar disorder and agitation in dementia, with preclinical work in other mood disorders. According to EvaluatePharma’s consensus 2022 worldwide sales are forecast to reach $2.5bn, $1bn of which are through partnering the drug in Europe. It has an NPV of $3.4bn, nearly double Intra-cellular’s market cap…"

 

Changing Landscape for Generic-Drug Makers Creates Opportunities  – The Street, August 8, 2016

"In its October review of the industry, EvaluatePharma listed the top 20 generics companies, based on 2014 worldwide revenue…"

 

Merck’s Keytruda gets FDA nod for head and neck cancer  – The Pharma Letter, August 9, 2016

"First approved in 2014, both Keytruda and Opdivo are forecast by EvaluatePharma to be among the top 20 best-selling drugs in the world by 2020…"

 

Istar Flies Towards Next-Gen Glaucoma Surgery Device – Seeking Alpha, August 9, 2016

“We are behind, it’s true,” he tells EP Vantage. “But I think we bring to the equation a next-generation MIGS solution, which will raise the bar significantly over current-generation MIGS in terms of response rate…”

 

NIH shuts down facility used to produce drugs for clinical trials – BioPharmaDIVE, August 10, 2016

“A laboratory at the National Cancer Institute and a National Institute of Mental Health facility were also caught up in the NIH's review. As a result of the NIH's efforts to check compliance, violations were found in both facilities, leading to a suspension of work. The suspension affected 13 clinical studies tied to Kite Pharma and Lion Biotechnologies, but five have since restarted, according to EP Vantage…”

 

2016 domestic and foreign medical device industry, market size and business ranking – md.tech-ex.com, August 10, 2016

“EvaluateMedTech according to statistics, in 2015 the global medical device sales volume of $ 390.3 billion, 2011--2015 global medical device steady growth in sales volume, compound annual growth rate (CAGR) of 1.90%. The size of the market is expected to grow to $ 477.5 billion in 2020, it will be presented during the 2015-2020 compound annual growth rate of 4.1%...”

 

Dems v. GOP on New Drugs  – WSJ, August 11, 2016

"Notice that the Democratic platform fails to "recognize" the vital importance of private funding. EvaluatePharma estimates the private sector will invest $144 billion this year in biomedical research. That’s more than four times as much as the National Institutes of Health’s $32.3 billion a year in grants and in-house research…"

 

Portola Approval And Headache Data From Lilly  – Seeking Alpha, August 12, 2016

"Since its 2013 float Portola is up 59%. Andexxa is its lead asset, and 2022 sales are forecast to reach $864m, according to EvaluatePharma sellside consensus. Of this forecast $129m is from partnering outside the US; Bristol-Myers Squibb and Pfizer have rights in Japan…"

 

Lilly Setback Underlines Pfizer's Strong Lead In Cyclin Inhibition  – Seeking Alpha, August 12, 2016

"In fact, consensus forecasts from EvaluatePharma reveal that no major analyst had been forecasting sales for abemaciclib before 2018 anyway. LEE011, which Novartis has said will be filed this year, was always seen as more likely to reach the market first…"

 

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing  – STAT, August 12, 2016

"Worldwide prescription drug sales are forecast to reach almost $1 trillion by 2020, with a compounded annual growth rate of 4.8 percent, according to Evaluate Pharma…"

 

China VS World, the medical device industry rank status at a glance! – md.tech-ex.com, August 15, 2016

“EvaluateMedTech according to statistics, in 2015 the global medical device sales volume of $ 390.3 billion, 2011--2015 global medical device steady growth in sales volume, compound annual growth rate (CAGR) of 1.90%. The size of the market is expected to grow to $ 477.5 billion in 2020, it will be presented during the 2015-2020 compound annual growth rate of 4.1%...”

 

Pfizer heads back to school with Trumenba vaccination campaign  – FiercePharma, August 15, 2016

"That narrow backing--which limited sales potential--was not what Pfizer and GSK were hoping for. Trumenba recorded $29 million in sales in 2015, up from $16 million in 2014, according to EvaluatePharma…"

 

Hepatitis B Developers Try To Repeat Gilead's Hep C Trick  – Seeking Alpha, August 16, 2016

"Nothing could be further from the truth, and a search of EvaluatePharma reveals Roche to be one of the most prominent developers of hepatitis B therapeutics ..."

 

CVRx Holds Its Nerve – Seeking Alpha, August 16, 2016

“CVRx is developing an implantable device for treating heart failure and hypertension, diseases poorly served by current drugs. So it is no wonder it has seen interest from big pharma, counting Action Potential Venture Capital – a specialized venture arm of GlaxoSmithKline (NYSE:GSK) – and Johnson & Johnson (NYSE:JNJ) Innovation among its investors. “J&J has invested in every single round of financing since 2007,” CVRx's chief executive, Nadim Yared, tells EP Vantage…”

 

Mixed six months for pharma and medtech  – Cambridge News, August 17, 2016

"The second half promises further turmoil with nervousness growing ahead of the US presidential election - both candidates have promised to train their sights on the healthcare sector - according to first half reviews of 2016 from EP Vantage, the editorial arm of life science market intelligence firm Evaluate…"

 

ReliantHeart Relies On Tech To Lure Buyer  – Seeking Alpha, August 17, 2016

"Does my phone ring? Yes,” chief executive Rodger Ford tells EP Vantage. “There’s a lot of interest, but what I need to do is get my head down and concentrate on getting the job done.” That job is launching the aVAD in Europe in September, as well as preparing for a US trial slated to start in the first quarter of 2017. Further into the future, the company is developing a wireless device that Mr Ford believes could revolutionize the field…”

 

Decision Time For Acacia As U.S. Filing Approaches  – Seeking Alpha, August 17, 2016

“If all goes to plan in the next few months Acacia could soon become a rare beast in the UK – a small drug developer in possession of an internally developed, US-approved product. Baremsis, the company’s anti-sickness treatment, will be filed with US regulators in the next six months, chief executive Julian Gilbert tells EP Vantage...”

 

Slimmed-Down Big Pharma Starts Growing Again  – Seeking Alpha, August 17, 2016

“On the one hand, big pharma seemed to have got comfortable with itself again, and after years of slimming down the sector’s biggest groups by and large became net recruiters, EP Vantage’s annual analysis reveals (see tables below). However, the most productive employers – big cap biotech – ratcheted up the efficiencies, suggesting that perhaps they could see the end in sight…”

 

Indivior's Addiction To The Opioid Market Is Paying Dividends  – Seeking Alpha, August 17, 2016

"The second half promises further turmoil with nervousness growing ahead of the US presidential election - both candidates have promised to train their sights on the healthcare sector - according to first half reviews of 2016 from EP Vantage, the editorial arm of life science market intelligence firm Evaluate…"

 

Crucial Patent Ruling On Copaxone And PDUFA For Parsabiv  – Seeking Alpha, August 18, 2016

"According to consensus from EvaluatePharma 2022 sales are forecast to reach $423m. Sensipar’s forecast sits at $442m in 2022, just a third of the $1.4bn it sold last year…"

 

No Antidote To Portola's Bleeding As FDA Rejects Andexxa  – Seeking Alpha, August 18, 2016

"Betrixaban’s mixed phase III results spurred losses earlier this year, although the group says it plans to submit the blood thinner for approval in the US and Europe by the end of 2016 (Precision medicine takes a scalp as Portola’s results confuse,March 24, 2016). Andexxa represents a bigger prize, as its net present value is $2bn to betrixaban’s $1.2bn, according to EvaluatePharma…"

 

After 2015’s ‘breakthrough’ year for pharma approvals, will 2016 see a dip?  – Pharmaphorum, August 18, 2016

"The immuno-oncology drug was approved for treatment of locally advanced or metastatic urothelial carcinoma (mUC) and Evaluate Pharma predicts it could hit revenues of $2.87 billion by 2021…"

 

Roche Has a Big Lead in the Evaluation of NPV of R&D Pipelines of 11 Global Pharmaceutical Enterprise  – CPhI, August 19, 2016

"In combination with EvaluatePharma’s evaluation of the global drug R&D pipelines and the NPV of the R&D pipelines of the 11 big pharmaceutical companies, the total NPV of the global drugs in development reach USD 555.4 billion (see the following figure for NPV of different phases), and the NPV of R&D pipelines of the 11 big pharma even reaches USD226 billion, accounting for 40%..."

 

Rapport: Medicinal og biotek har toppet  – Finanz, August 19, 2016

"Det er konklusionen i en ny rapport fra markedsanalyseselskabet Evaluate Pharma, som ser tilbage på de første seks måneder af 2016…"

 

Amerikansk virksomhed ansætter 100 personer ekstra i Danmark  – Medwatch, August 19, 2016

 

Pfizer Acquires Medivation for $14 Billion (PFE, MDVN)  – Investopedia, August 21, 2016

"According to Evaluate Pharma, Xtandi, could be one of the top-selling cancer drugs by 2020. On the other hand, the equal prostate-cancer treatment against Xtandi is produced by Johnson & Johnson called as Zytiga. The analysts believe that J&J may pose a threat to Xtandi in the short-run…"

 

Look back at pharma news to August 19  – The Pharma Letter, August 21, 2016

"Vertex Pharmaceuticals’ miss in a hard-to-treat group of cystic fibrosis patients underscores some important catalysts for its next-generation combinations, noted EP Vantage, the editorial arm of the Evaluate group…"

 

Pfizer Reportedly Nears $14 Bln Deal To Acquire Medivation  – Nasdaq, August 21, 2016

"According to EvaluatePharma, Xtandi could be one of the top-selling cancer drugs by 2020. Meanwhile, Xtandi has a rival in prostate-cancer treatment from Johnson & Johnson called Zytiga. As per reports, Xtandi would complement Pfizer's breast-cancer..."

 

Pfizer buys manufacturer of cancer drugs  – Trend.SK, August 22, 2016

"Cancer treatment for the pharmaceutical industry is one of the largest markets.According to data from EvaluatePharma's annual revenues are around $ 80 billion and annual growth of about ten percent. Cancer is among the top ten world's "killer" in the US is the second most common disease causing death…"

 

Pfizer acquires biotech company Medivation  – Capital.bg, August 22, 2016

"According to EvaluatePharma sales in this sector amounted to approximately EUR 80 billion. Dollars and grow by about 10% per year…"

 

Pfizer compra fabricante de medicamentos contra el cancer  – El Nuevo Herald, August 22, 2016

"... farmacéutica, con ventas del orden de los $80,000 millones al año y un crecimiento anual superior al 10 %, según datos de la firma EvaluatePharma…"

 

Pfizer compra fabricante de remédios contra o câncer Medivation  – Globo, August 22, 2016

"Os remédios contra o câncer representam um dos maiores mercados da indústria farmacêutica, com vendas na ordem dos US$ 80 bilhões por ano e um crescimento anual superior a 10%, segundo dados da companhia EvaluatePharma…"

 

Pfizer Agrees to $14 Billion Price for Medivation  – Marea Informative, August 22, 2016

"Cancer has become one of the biggest markets in the pharmaceutical industry with sales worldwide reaching close to $80 billion annually and growing over 10% each year, indicated a report from EvaluatePharma…"

 

Would Pfizer Inc. (PFE) Acquire Medivation Inc (MDVN) for $14 Billion?  – TCC, August 22, 2016

"The company is optimistic that the molecule will be blockbuster drug after its launching. According to EvaluatePharma, oncology is one the lucrative markets of pharmaceutical industry generating a sale volume of $80 billion annually…"

 

Pfizer Medivation Deal at $14 Billion: Boosts Pfizer's Cancer Drug Portfolio  – FX News Call, August 22, 2016

"The market has an annual growth of more than 10 percent, according to EvaluatePharma. The Pfizer Medivation deal also boosts Pfizer CEO Ian Read's efforts to expand the innovative side of the company's business. Read's plans include splitting Pfizer's.."

 

Oncology Drugs Motivate Pfizer's $14-Billion Deal For Medivation  – MediaPost Communications, August 22, 2016

"Xtandi, which Astellas Pharma also sells [and gets 50% of the profit], could be one of the top-selling cancer drugs by 2020, according to EvaluatePharma. But J&J is developing a new prostate-cancer drug that could pose a threat to Xtandi, according to ..."

 

Pfizer Pharma acquires Medivation for $14 billion  – Fox News Latino, August 22, 2016

"Cancer treatment products represent one of pharma industry biggest markets, with sales totalling $80 billion per year and a annual growth of over 10 percent, according to the company EvaluatePharma…"

 

Pfizer fa sua Medivation, affare da $14 miliardi  – Pharmastar, August 22, 2016

"Il cancro è uno dei più grandi mercati del settore farmaceutico con un fatturato a livello mondiale pari a circa 80 miliardi di $ l'anno e in crescita di oltre il 10% l'anno, secondo quanto riporta la società di ricerche di mercato EvaluatePharma…"

 

Pfizer Inks Deal For Medivation Acquisition  – The Cerbat Gem, August 22, 2016

"Medivation is one of the few independent biotech companies with a cancer treatment that is already approved and selling well. Medivation is the creator of leading prostate-cancer drug Xtandi. Xtandi generated U.S. net sales of $330.3 million in the second quarter. According to EvaluatePharma, Xtandi could be one of the top-selling cancer drugs by 2020. Pfizer will also get access to Talazoparib, another breast cancer treatment under development…"

 

Pfizer to Buy Medivation, Inc Pharmaceutical Company is not Far Way…  – Biostandups, August 22, 2016

"Xtandi has held its own against a rival prostate-cancer treatment from Johnson & Johnson called Zytiga. Xtandi, which Astellas Pharma Inc. also sells, could be one of the top-selling cancer drugs by 2020, according to EvaluatePharma…"

 

Pfizer Near $14 Billion Deal for Biotech  – WSJ, August 22, 2016

"Cancer is one of the pharmaceutical industry's biggest markets with world-wide sales amounting to roughly $80 billion a year and growing more than 10% annually, according to EvaluatePharma… Xtandi has held its own against a rival prostate-cancer treatment from Johnson & Johnson called Zytiga. Xtandi, which Astellas Pharma Inc. also sells, could be one of the top-selling cancer drugs by 2020, according to EvaluatePharma…"

 

La farmacéutica Pfizer compra Medivation por unos 14.000 millones de dólares  – Heraldo, August 22, 2016

"Los medicamentos contra el cáncer representan uno de los mayores mercados de la industria farmacéutica, con ventas del orden de los 80.000 millones de dólares al año y un crecimiento anual superior al 10 %, conforme a datos de la firma EvaluatePharma..."

 

Pfizer buying Medivation 14,000 million  – Archy World News, August 22, 2016

"Cancer drugs represent one of the largest markets in the pharmaceutical industry, with sales of around 80,000 million dollars a year and an annual growth rate of over 10%, according to data firm EvaluatePharma…"

 

Pfizer опять взялся за старое  – Expert Online, August 22, 2016

“Тем не менее издание EvaluatePharma считает, что препарат имеет потенциал для увеличения ежегодного объема продаж более чем вдвое до $5,7 млрд.EvaluatePharma считает, что Xtandi, вероятно, станет одним из самых продаваемых лекарственных средств от рака к 2020 году …”

 

Pfizer compra Medivation por cerca de US$ 14 bilhões  – entretenimientobit, August 22, 2016

"Os medicamentos contra o câncer encarnam um dos maiores mercados da indústria farmacêutica, com vendas na ordem dos US$ 80 bilhões por ano e um crescimento anual superior a 10%, segundo dados da empresa EvaluatePharma…"

 

Pfizer Adds Key Drug for Cancer in $14 Billion Deal  – Dieta Plana, August 22, 2016

"Los medicamentos contra el cáncer representan 1 de los mayores mercados de la industria farmacéutica, con ventas del orden de los 80.000 millones de dolares al año y un incremento anual suprema al diez %, conforme a datos de la firma EvaluatePharma…"

 

Pfizer koupí za 14 mld. USD výrobce léků na rakovinu Medivation  – Deniz.cz, August 22, 2016

"Léčba rakoviny je pro farmaceutický průmysl jedním z největších trhů. Podle údajů EvaluatePharma zde roční příjmy dosahují zhruba 80 miliard dolarů a ročně rostou o deset procent…"

 

Pfizer, mega acquisizione  – America Oggi, August 23, 2016

"Quello dei farmaci contro il cancro è uno dei mercati più grandi dell’industria, con vendite annue che nel mondo ammontano a circa 80 miliardi di dollari e una crescita di oltre il 10%, secondo EvaluatePharma. ..."

 

Pfizer Expands Cancer Drug Portfolio with the Acquisition of Medivation - Latest Report on Pfizer  – Baystreet, August 23, 2016

"Since receiving approval from the U.S. Food and Drug Administration in 2012, Xtandi has treated 64,000 men for advanced metastatic prostate cancer in the U.S. alone. Xtandi has the potential to be one of the top-selling cancer drugs by 2020, according to EvaluatePharma…"

 

Who's Next After Medivation?  – Seeking Alpha, August 23, 2016

"Actually, the optimists might have a point. The Medivation auction revealed big companies that, having lost out, might now be keener than ever to buy. Yesterday’s stock rises in Incyte (NASDAQ:INCY), Biomarin (NASDAQ:BMRN) and Exelixis (NASDAQ:EXEL) point to several possible targets, and an analysis of EvaluatePharma reveals others (see table below)…"

 

Pfizer compra Medivation por cerca de US$ 14 bilhões  – Tomar TV, August 22, 2016

"O câncer é um dos maiores mercados para a indústria farmacêutica, cujas vendas chegam a US$ 80 bilhões por ano e apresentam crescimento médio de 10% ao ano, de acordo com a EvaluatePharma…"

 

Adquiere Pfizer a Medivation por 14 mmdd – El Siglo De Durango, August 22, 2016

"Los medicamentos contra el cáncer representan uno de los mayores mercados de la industria farmacéutica, con ventas del orden de los 80,000 millones de dólares al año y un crecimiento anual superior al 10 %, según datos de la firma EvaluatePharma…"

 

Pfizer compra Medivation por unos 14.000 millones de dólares  – Intereconomia, August 22, 2016

"Los medicamentos contra el cancer representan uno de los mayors mercados de la industria farmaćeutico, cos ventas del orden de los 80,000 millones de dólares al año y un crecimiento annual superior al 10%, según datos de la firma EvaluatePharma…"

 

Pfizer anuncia compra da Medivation por US$ 14 bilhões  – Dinheiro, August 22, 2016

"O câncer é um dos maiores mercados para a indústria farmacêutica, cujas vendas chegam a US$ 80 bilhões por ano e apresentam crescimento médio de 10% ao ano, de acordo com a EvaluatePharma…"

 

Pfizer compra fabricante de remédios contra o câncer Medivation  – Circuitomatagrosso, August 22, 2016

"Os remédios contra o câncer representam um dos maiores mercados da indústria farmacêutica, com vendas na ordem dos US$ 80 bilhões por ano e um crescimento anual superior a 10%, segundo dados da companhia EvaluatePharma…"

 

Pfizer chce být jedničkou v onkologii. Díky akvizici za 14 miliard dolarů  – Euro.cz, August 22, 2016

“Podle údajů EvaluatePharma zde roční příjmy dosahují zhruba 80 miliard dolarů a ročně rostou o deset procent. Rakovina patří celosvětově mezi deset největších „zabijáků…”

 

A Day Of Soul-Searching For CAR-T Bulls – Seeking Alpha, August 22, 2016

“Novartis remains committed to its lead CAR-T programmes, and does not agree that they will now be sidelined, the spokesperson told EP Vantage, insisting that the move reflected broader changes at the group…”

 

Price Gouging and the Dangerous New Breed of Pharma Companies  – Kopitiam Bot, August 23, 2016

"According to EvaluatePharma’s 2015 Orphan Drug Report, this market makes up 20.2% of total global prescription drug sales and is growing by 11.7% annually, nearly double the growth rate of the global prescription drug market overall..."

 

Pfizer compra una farmacéutica especailizada en el tratamiento del cancer por 14.000 millones  – Canal Salud, August 23, 2016

"Los medicamentos contra el cáncer representan uno de los mayores mercados de la industria farmacéutica, con ventas del orden de los 70.000 millones de euros al año y un crecimiento anual superior al 10 %, según datos de la firma EvaluatePharma…"

 

Фарминновации -- опыт BigPharma и российские инициативы  – Remedium, August 23, 2016

“По прогнозу аналитиков Evaluate Pharma, к 2019 г. его продажи составят 1,6 млрд долл., поставив препарат в ряд блокбастеров (табл. 1)…”

 

Pfizer acquires cancer drug producer  – The New Economy, August 23, 2016

"Cancer is one of the biggest markets in the pharmaceutical sector, according to EvaluatePharma…"

 

Big Pharma's competition to buy new cancer drugs  – Mag-Series-USA, August 24, 2016

"According to EvaluatePharma, oncology is one the lucrative markets of pharmaceutical industry generating a sale volume of $80 billion annually…"

 

Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy?  – FiercePharma, August 24, 2016

"Does Pfizer know something AstraZeneca doesn’t? After all, AstraZeneca needs new drug brands and pipeline meds as much as any company in Big Pharma. Merrem may be a declining product, but it still brought in $241 million last year. The company didn’t break out Zinforo revenue, but EvaluatePharma lists its 2015 sales at more than $100 million. Meanwhile, Allergan has been reasonably enthused about the newer suite of antibiotics and its prospects in the U.S., where it markets them under the brand names Teflaro and Avycaz…"

*Also appeared on Wessex Life Science Cluster

 

FDA knocks back Amgen's chronic kidney disease treatment – PMLive, August 25, 2016

“A recent EP Vantage report listed the drug among the most valuable filed assets in the pharma industry for 2017, assuming Amgen can persuade Medicare in the critical US market that the drug can slot into the bundled payment system set aside for dialysis care...”

 

Therapy Focus - Seeking Sustained Success In The Opioid Dependence Market – Seeking Alpha, August 25, 2016

“Heavy hints have been dropped that these new long-acting opioid antagonists will be launched at a similarprice to once-monthly injected schizophrenia therapies. Invega Sustenna, Johnson & Johnson’s (NYSE:JNJ) once-monthly shot, was sold last year to US government buyers for $1,265-1,772 per unit, while Otsuka’s (OTC:OSUKF) Abilify Maintena came in at $1,000-1,400, according to EvaluatePharma…”

 

Teva Holds Cracking Door On Copaxone Generics – Seeking Alpha, August 25, 2016

“EvaluatePharma’s consensus of sellside analysts had the combined US 20mg and 40mg sales shrinking from $3.2bn in 2015 to $986m in 2022. In the meantime, as patent protections have faded Teva has pushed through price increases, with annual costs surging from $37,000 a year in 2010 to $72,000 in 2015. It is no wonder that generics companies saw Copaxone as a ripe target…”

 

Denali Lets Rip With Biggest Funding Round – Seeking Alpha, August 25, 2016

“But there is obviously still an appetite for novel drugs for neurodegenerative diseases, and Denali is one of only a handful of players targeting the receptor-interacting protein (Rip) kinase family, according to EvaluatePharma (see table below)…”

 

Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA – Xconomy, August 26, 2016

“According to a 2015 report from EvaluatePharma, the market for drugs for rare, or “orphan” diseases, as they’re known, has been growing by 12 percent every year and is expected to reach $178 billion worldwide by 2020. The small populations of patients with those diseases, combined with a lack of alternative treatments, means the drugs typically command very high prices—on average, an estimated $111,820 per patient, per year between 2010 and 2014, according to the report. Twenty-one orphan drugs were approved in 2015, a record for the second straight year…”

 

Look back at pharma news to August 26 – The Pharma Letter, August 28, 2016

“AstraZeneca’s latest divestment has allowed Pfizer to pick up a bargain in ex-US rights to five novel antibiotics, though sales could struggle to reach forecast levels if the drugs are reserved for emergencies, which might especially be the case in the European Union, commented EP Vantage, the editorial arm of the Evaluate group…”

 

Pharma: An Overview Of The Current Uncertainty – Market Mogul, August 29, 2016

“Data by EvaluatePharma shows that the number of new drugs approved increased by 103.6% between 2005 and 2015. Furthermore, low-interest rates have also helped propel the upward trend in overall M&A activity by lowering borrowing costs…”

 

Picking Up The Pieces In Stem Cell Therapy – Seeking Alpha, August 29, 2016

“Any resources that will be needed to further develop C-Cure will need to come from an external strategic or financial partner, in the form of a licensing out, an M&A, a joint venture or [another] structure,” a Celyad spokesperson told EP Vantage…”

 

MassBio: drug development pipeline, candidates in clinical trials on the rise – Outsourcing-Pharma, August 30, 2016

“Snapshot statistics are compiled yearly by MassBio from sources including EvaluatePharma, National Institutes of Health, the US Bureau of Labor Statistics, the...”

 

Prothena Builds Case For Amyloidosis Valuation – Seeking Alpha, August 30, 2016

“EvaluatePharma’s consensus of sellside analysts puts 2022 sales of NEOD001 at $946m, giving it a net present value of $2.9bn – substantially above Prothena’s market capitalization of $1.7bn. The company’s shares have fallen 30% since peaking last November, but still stand at nearly seven times their value when the former Elan spun the group out in December 2012…”

 

Handys? Samsung setzt jetzt auf Medikamente – Medinside, August 31, 2016

“Gemäs einer Studie von Evaluate Pharma, die Samsung verbreitet, werden die Verkäufe mit Biopharmazeutika bis 2020 um jährlich 8 Prozent auf 278 Milliarden Dollar wachsen…”

 

 July 2016

 

Tesaro Shows That Lynparza Was No Fluke  – Seeking Alpha, July 1, 2016

"However, only half of niraparib’s $1.1bn 2022 consensus revenue forecast comes from ovarian cancer, EvaluatePharma data suggest. The key to meeting expectations for all Parp inhibitors is additional indications like breast cancer, and here the future is far less certain…"

 

More Than Ever Shire Needs Unusual Focus On ADHD Franchise  – Seeking Alpha, July 1, 2016

"The reasons for freezing and resuscitating this agent are not exactly clear. However, the EvaluatePharma consensus of sellside analysts forecasts $323m in sales in 2022; this morning, Bryan Garnier analysts estimated a potential $500m in sales by 2020…"

 

5 Medtech Stocks to Watch Out for in 2H16  – ZACKS, July 5, 2016

"As far as the Q2 earnings results are concerned, Medical is one of the 6 Zacks sectors (comprising a total of 16 sectors) that is expected to record earnings growth, while the S&P 500 itself is projected to witness a decline. Moreover, as per EvaluateMedTech’s latest report, the global Medtech industry is expected to grow at a CAGR of 4.1% from 2014 to reach a sales value of $477.5 billion in 2020…"

 

Price Gouging and the Dangerous New Breed of Pharma Companies  – Harvard Business Review, July 6, 2016

"According to EvaluatePharma’s 2015 Orphan Drug Report, this market makes up 20.2% of total global prescription drug sales and is growing by 11.7% annually, nearly double the growth rate of the global prescription drug market overall. Strikingly, 44% of new drugs approved in 2014 had orphan status, with seven of the 10 best-selling drugs being approved under the ODA…"

 

Hvornår bliver biotekbranchen voksen?  – MedWatch, July 6, 2016

 

Takeda snatches up Belgian Cell therapy for Crohn’s Disease  – Labiotech, July 6, 2016

"Crohn’s disease is one of the fastest-growing therapeutic areas, with a market expected to be worth over €5Bn in 2017 (according to Evaluate Pharma). So no wonder it’s quite a coveted market, along withother inflammatory conditions…"

 

Lion The First Beneficiary Of NCI's Trial Resumption  – Seeking Alpha, July 6, 2016

"Four trials for which Kite Pharma (NASDAQ:KITE) has a separate CRADA remain suspended, but should reopen within three months, an NCI spokesperson told EP Vantage…"

 

First U.S. Approval For Liquid Biopsy Is Just The Start For Roche  – Seeking Alpha, July 6, 2016

"The approval is also important to the company in symbolic terms. It is the leader in the IVD segment with annual sales of more than $9bn last year, nearly twice as much as its closest rival, Abbott. This margin is forecast to be maintained in 2022, EvaluateMedTech data show – and one of the keys to this success is innovation and being the first mover…"

 

Five NCI cell therapy studies resume production after April halt  – BioPharmaDIVE, July 7, 2016

"So far, Lion Biotechnology's three affiliated studies have resumed enrollment, but Kite Pharma still has four affiliated studies halted, EP Vantage said. An NCI spokesperson told the publication that all studies should resume within three months…"

 

Smaller Medtechs In Charge Of Their Own Destiny  – Seeking Alpha, July 7, 2016

"Share price changes are muted compared with previous occasions on which EP Vantage has performed this analysis. The leader of the mid-caps is Teleflex (NYSE:TFX) with a jump of just 35%.."

 

Bristol-Myers Buys Back Medarex Discard  – Seeking Alpha, July 7, 2016

"Yet EP Vantage’s last examination of the fertile area of immuno-oncology combination trials suggests that Bristol-Myers could have the IL-8 space all to itself…"

 

Medivation opens books to Sanofi  – European Biotechnology News, July 7, 2016

" According to estimates of Evaluate Pharma, revenues for Xtandi alone could rise to US$4.78bn a year by 2020…"

 

Bristol-Myers Buys Back Medarex Discard  – Seeking Alpha, July 7, 2016

"This might be because there is virtually no other work with IL-8-targeting agents. A scan of the pipeline in EvaluatePharma shows that only one other is in active oncology research in ProNAI Therapeutics’ (NASDAQ:DNAI) PNT600, and that group is more focused on AS-141, an asset it licensed in May. ProNAI shares declined 4% yesterday…"

 

Medivation cancer drug ‘best in class’ – CEO  – Pharmaphorum, July 7, 2016

"Despite Hung’s bullishness, EvaluatePharma last year said that consensus forecasts for talazoparib are just below $200m per year by 2020 – comparatively low compared with Xtandi which is expected to approach $5 billion a year by that time…"

 

America's 5 most-expensive prescription drugs  – CNBC, July 7, 2016

"Prescription drug prices have soared, often exceeding US average annual income. These are the five most expensive. CNBC's Dina Gusovsky reports… Source: EvaluatePharma…"

 

Medical Device Consolidation Frenzy: Here's How to Play it  – ZACKS, July 7, 2016

"Dearth of venture funding: As if the smaller MedTech players didn’t have trouble enough, the growing difficulties related to the venture funding landscape have made their lives even worse. 2015’s data by Evaluate MedTech shows that the value of venture financing dropped 14% in in the first half with a 13% decrease in deal count. This was in fact part of an ongoing trend of falling investment observed over the past few years, affecting the early-stage businesses the most. This funding situation is getting more challenging day by day, forcing smaller companies to join the big hands to survive and pursue product development.."

 

Her er Europas nye blockbustere  – Jyllands Posten, July 8, 2016

"Det europæiske lægemiddelmarked vil vokse støt det kommende halve årti, mener Evaluate Pharma, som har kigget på hvilke midler, der vil dominere salgsstatistikkerne i 2022. En dansk aktør forventes at drive broderparten af væksten i ét bestemt markedssegment…"

 

U.K. Sees Huge Series As In 2016  – Seeking Alpha, July 8, 2016

"The $20m series A venture round closed by Cambridge Medical Robotics today is the second largest for a UK-based company of the past decade – and the second largest this year. Data compiled by EvaluateMedTech show that cancer genomics specialist Inivata takes the top spot, hauling in a record $45m series A in January…"

 

Top R&D innovators in med tech  – FierceBiotech, July 8, 2016

"This list is based on data from EvaluateMedTech, to which we are grateful. The R&D budget figures are specifically for medical devices and diagnostics, but are structured to exclude life science research tools. Some data for companies that do not have a calendar fiscal year has been annualized…"

 

Value Of Medtech Mergers Down 80%  – Seeking Alpha, July 8, 2016

"Of course, some large mergers have been conducted. Dentsply’s (NASDAQ:XRAY) $5.5bn merger with Sirona Systems (NASDAQ:SIRO) has completed to produce the second largest maker of dental products with worldwide sales of $2.4bn last year. With an impressive growth rate of 13%, Dentsply Sirona is forecast to leapfrog Danaher (NYSE:DHR) to take the top spot in 2022 when it will do $5.6bn of business according to EvaluateMedTech data…"

 

Look back at pharma news to July 8  – The Pharma Letter, July 10, 2016

"Also commenting, EP Vantage, the editorial arm of the Evaluate group, said Juno Therapeutics seems optimistic that a clinical hold on its lead CAR-T candidate will delay the project rather than scuppering it altogether..."

 

Vesneo's Decision Date And Fostamatinib's Next Try  – Seeking Alpha, July 11, 2016

"Sales of marketed glaucoma drugs are expected to shrink by 2% a year between 2015 and 2022, so the partners will have some work to do. EvaluatePharma forecasts Vesneo sales of $336m in 2022…"

 

European pharma market projected to grow from €169bn in 2015 to €206bn in 2022  – Manufacturing Chemist, July 11, 2016

"The European pharmaceutical market is set to grow from €169 billion in 2015 to €206bn in 2022, according to a new report from life science market intelligence firm Evaluate..."

 

Sagent Pharmaceuticals, of Schaumburg, to be acquired by Japanese company  – Chicago Tribune, July 11, 2016

"With 2014 sales of $1.2 billion, Nichi-Iko is the 20th largest generics company in the world, according to EvaluatePharma. It has products in development known as biosimilars that are copycat versions of biologic drugs…"

 

MedTech Industry Stock Outlook - July 2016  – ZACKS, July 11, 2016

"A recent EvaluateMedTech World Preview claims that the MedTech space is positioned for impressive growth in the near term. At a glance, MedTech sales worldwide are expected to grow at a CAGR of 4.1% to $477.5 billion by 2020…"

 

M&A - Value Of Deals Looks Healthy But Number Meager  – Seeking Alpha, July 12, 2016

"Pharma and biotech companies announced transactions worth $22.1bn, according to EvaluatePharma, a figure achieved without any big deal to pump up the total – AbbVie’s (NYSE:ABBV) $9.8bn takeout of Stemcentrx was the largest. This quarterly tally looks pretty respectable when looking back over the last few years, an encouraging sign for an industry concerned about a slowdown…"

 

Who Splashed The Cash At The Top Of The Market?  – Seeking Alpha, July 13, 2016

"The table below slices EvaluatePharma M&A data a couple of ways, to capture the average price paid for pharma and biotech companies over the last decade – the analysis excludes medtech and diagnostic companies, focusing only on firms developing human therapeutics. It also removes the very big deals that skew the numbers upwards…"

 

Approval Makes Xiidra The Apple Of Shire's Eye  – Seeking Alpha, July 13, 2016

"Shire has also prevailed in another of its goals, preventing itself being acquired with its own purchase of Baxalta, which finally completed in June. However, the companies’ joint pipelines post-Xiidra’s approval look rather thin, with no more blockbusters-in-waiting according to EvaluatePharma sellside forecasts..."

 

Ultragenyx Hopes Rare Strategy Will Smooth Path To Approval  – Seeking Alpha, July 15, 2016

"With only around 200 affected patients worldwide and 2022 revenues pegged at $66m, rhGUS is far from being Ultragenyx’s biggest pipeline prospect: this honour goes to UX007, or triheptanoin, which is soon expecting phase II results in long-chain fatty acid oxidation disorders and is forecast to bring in $418m by 2022 according to EvaluatePharma sellside consensus (Event – Ultragenyx looks to data from its biggest projects, May 5, 2016)…"

 

Swarm Of Small Players Clouds Biosimilar Forecasts  – Seeking Alpha, July 15, 2016

"Forecasts have been made, of course. EvaluatePharma’s consensus of sellside analysts shows $7bn of biosimilar sales by 2022, with copycats of Humira, Lantus and Remicade contributing almost half of this figure. However, these relatively near-term expectations mostly concern products on or nearly at the market, and most of these are indeed in the hands of the bigger players…"

 

Brief: Orphan Drugs Finding Home In Markets: Could Be 20% Of All Sales By 2020  – Intellectual Property Watch, July 15, 2016

"Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market "could only dream about" with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage…"

 

Phase III Data For Amicus And Ocular's FDA Approval  – Seeking Alpha, July 15, 2016

"There are no approved medications for EB, and treatment involves bandaging and cleaning open wounds to prevent infection, alongside pain relief. Sellside consensus forecasts from EvaluatePharma point to 2022 sales of $283m. Amicus reckons that it has a $1bn-plus sales potential, with first-in-class standing and strong support from physicians and payers…"

 

Therapy Focus - Another Try For FGFR Inhibitors  – Seeking Alpha, July 15, 2016

"Since EP Vantage last wrote about this class the leading candidate, Bristol-Myers Squibb’s (NYSE:BMY) brivanib, has been abandoned. However, a new generation of late-stage agents has emerged, and biomarker tests to detect tumors expressing FGFR genetic alterations have helped to identify a subset of patients that could show a greater benefit…"

 

Look back at pharma news to July 15  – The Pharma Letter, July 17, 2016

"Pharma and biotech companies announced transactions worth $22.1 billion, according to EvaluatePharma, a figure achieved without any big deal to pump up the total – AbbVie’s $9.8 billion takeout of Stemcentrx was the largest…"

 

Ziopharm Hopes Gene Therapy Is Still A Going Concern  – Seeking Alpha, July 19, 2016

"But even if things work out in Ziopharm’s favour, Ad-RTS-hIL-12 still looks set to fall short of early hopes – once forecast to bring in $1.2bn by 2020, current EvaluatePharma sellside consensus sits at just $203m in 2022, and could fall even further on the news…"

 

Celgene Pays Through The Nose For A Hand In Immune Checkpoints  – Seeking Alpha, July 20, 2016

"If there were multiple parties interested in JTX-2011 then Jounce looks to have had a strong bargaining position. JTX-2011 is one of just three Icos-targeting MAbs in development, EvaluatePharma data suggest…"

 

The End Of Another Chapter In Obesity Drug Development  – Seeking Alpha, July 21, 2016

"The only one of the current crop of obesity drugs that still holds significant promise is Novo Nordisk’s (OTCPK:NONOF) Saxenda, forecast to sell $175m this year and $791m in 2022, according to EvaluatePharma’s sellside consensus. Still, this is injectable and available separately for diabetes, implying a different market dynamic…"

 

Diurnal Keeps Its IPO Promises  – Seeking Alpha, July 21, 2016

"So far the spinout from Sheffield University has not disappointed. Last week Diurnal reported positive phase III data for its lead asset, Infacort, in pediatric adrenal insufficiency (NYSE:AI), moving European approval closer. Speaking to EP Vantage Martin Whitaker, its chief executive, says: "We are on track to deliver what we set out to do at IPO, which was to file for market authorization for Infacort by the end of this calendar year…"

 

Testing Lirilumab In Leukemia And Pridopidine In Huntington's  – Seeking Alpha, July 22, 2016

"When owned by Neurosearch this project was called Huntexil, and went through two large phase III trials where it failed on its primary endpoint of modified motor score, but performed better on the secondary, total motor score (EP Vantage Interview - NeuroSearch seeking path forward for Huntexil,April 13, 2011)…"

 

For The Real Relypsa Puzzle Look Beyond The Takeover  – Seeking Alpha, July 22, 2016

"Earlier this year Søren Tulstrup, Vifor’s chief executive, boasted to EP Vantage of a $1bn+ war chest (Vifor Pharma bets on portfolio before potential split, May 9, 2016). However, just weeks later Mr Tulstrup quietly left the company; today Galenica said Relypsa marked the final stage of its separation into Vifor and Galenica Santé…"

 

4 Medical Instrument Stocks to Bet on This Earnings Season  – Nasdaq, July 22, 2016

"A recent EvaluateMedTech World Preview claims that this space within medical device is positioned for impressive growth in the near term. At a glance, medical device sales worldwide are expected to grow at a CAGR of 4.1% to $477.5 billion by 2020…"

 

Look back at pharma news to July 22  – The Pharma Letter, July 24, 2016

"Rare disease specialist Ultragenyx Pharmaceutical has strong biomarker data and a trend towards functional improvement on its mucopolysaccharidosis type 7 treatment rhGUS, and must now try to convince regulators that this is enough for approval, noted EP Vantage, the editorial arm of the Evaluate group…"

 

Bristol-Myers to combo Opdivo, Yervoy with AbbVie's Rova-T in next-gen cancer cocktail trials  – FiercePharma, July 25, 2016

"For AbbVie, hitching to Opdivo’s wagon can’t hurt. With each new approval, Opdivo has racked up more impressive sales numbers. It brought in $942 million for Bristol-Myers in 2015, and it’s expected to hit $8.4 billion by 2020, according to EvaluatePharma…"

 

As EU Approval Moves Closer Are Governments Prepared For PrEP?  – Seeking Alpha, July 26, 2016

"In the US, where Truvada PrEP has been available since 2012, the drug is usually covered through either Medicaid or insurance programs, with the regimen costing in the region of $16,000 a year, according to EvaluatePharma's US sales data…"

 

Celgene gives up on lucrative new use for linchpin drug Revlimid, clouding hopes for $1B-plus revenue boost  – FiercePharma, July 26, 2016

"On its own, Revlimid has been expected to bring in more than $10 billion in 2020 sales, according to a report from EvaluatePharma. That could change as the drug either delivers, or fails to deliver, on the new indications Celgene is shooting for…"

 

Lilly CEO John Lechleiter to retire by year-end  – BioPharmaDIVE, July 27, 2016

"That pipeline is the result of heavy investment. Lilly poured 24% of its revenues into drug R&D in 2015, the third highest mark in the industry last year, according to EP Vantage…"

 

Will the UK ever produce a world-class biotech company?  – Pharmaphorum, July 28, 2016

"The sale of microchip company ARM Holdings has some lamenting the loss of that rare thing, a British world-class company. Can a new wave of biotech start-ups produce a company which can grow into a world-beater, or will they suffer the same fate? Andrew McConaghie reports… Read the BIA/Evaluate Pharma report Money, momentum and maturity: UK biotech financing and deals in 2015/16…"

 

With A New Attitude To Deals, Lilly Could Grow Stronger  – Seeking Alpha, July 29, 2016

"Risks remain, however, the most apparent being solanezumab. The Alzheimer’s antibody represents its second most-valuable pipeline asset, with a substantial $5.6bn NPV, according to EvaluatePharma…"

 

(NASDAQ:EPRS), Anavex Life Sciences Corp. (NASDAQ:AVXL)  – Voice Registar, July 29, 2016

"The Company’s current pipeline of biosimilar product candidates includes: BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); and additional undisclosed assets. The projected innovator or class sales for these products are estimated at almost $6 billion in global sales in 2020, according to EvaluatePharma®…"

 

TauRx Touts Second Chance To Prove Success  – Seeking Alpha, July 29, 2016

"TaurRx's chief executive, Claude Wischik, told EP Vantage that randomisation in the TRx-237-015 study had been balanced for geography, severity and use of symptomatic therapy, and thus each of these was tested as part of the prespecified secondary analysis…"

 

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs  – The Street, July 29, 2016

"But (and you knew this was coming), the ExteNet study has been changed, poked, prodded, raked over and generally fiddled with so many times that those five-year DFS data aren't reliable. EP Vantage writer Jacob Plieth dove into the statistical hocus pocus of ExteNet in this article, which is well worth the read..."

 

 June 2016

 

Celator Rewards Investors With Stunning Jazz Solo  – Seeking Alpha, June 1, 2016

"Indeed, EP Vantage can claim to have been prescient here, having also foreseen that the Vyxeos phase III result would make Celator a takeover target for a company seeking to establish a bridgehead in AML (Hail mighty Celator, the small cap that beat long odds, March 15, 2016)…"

 

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing  – MM&M, June 2, 2016

"EvaluatePharma analyst Jacob Plieth wrote that it was unclear if Novartis would aim to file CTL119 before CTL019 given that the drugmaker is the "furthest advanced" in the treatment class, which includes Juno Therapeutics and Kite Pharma, and switching could push off next year's expected filing date. The full study will be presented on Saturday…"

 

First Batch Of Drugs Primed In Europe  – Seeking Alpha, June 3, 2016

"While two of the products – Kite’s (NASDAQ:KITE) KTE-C19 and Biogen’s (NASDAQ:BIIB) aducanumab – are expected to be big sellers, the other two target rare diseases and do not yet have EvaluatePharma consensus forecasts. But drugs falling into the latter group are surely the ideal candidates for Prime…"

 

Bristol-Myers Squibb Co, Merck & Co., Inc: Oncology Market Might Touch $150 billion in 2020  – Business Finance News, June 3, 2016

"According to EvaluatePharma, Roche's Herceptin and Avastin, Enbrel by Pfizer and Amgen, Merck’s Januvia, Bristol-Myers Squibb's blockbuster Opdivo are in the illustrious list to be Oncology giants…"

 

Novartis joins Eisai to push Lenvima and Afinitor combo in U.S.  – FiercePharma, June 3, 2016

" Then granted it orphan product designation. But Eisai is testing it against other cancers and expects it to hit $1 billion in annual sales by 2020, although that is more than double a forecast from Evaluate Pharma, which pegs its sales at $424 million by 2019…"

 

Lungpacer Goes Live Following Early Data  – Seeking Alpha, June 3, 2016

"The FDA believes these patients are in a life-threatening situation and the Lungpacer technology has potential to save them," the group’s chief executive, Doug Evans, tells EP Vantage…"

 

Look back at pharma news to June 3 – The Pharma Letter, June 3, 2016

 

Industry on the brink of first CAR-T approval, but big obstacles remain – The Pharma Letter, June 3, 2016

 

Unternehmen im Wachstumsmodus hat ehrgeizige Pläne - Boersen Zeitung, June 4, 2016

"Und die Biopharmabranche wächst weiter kräftig. Im Durchschnitt 8 bis 9 % mehr Umsatz pro Jahr erwartet der Marktbeobachter Evaluate Pharma bis 2020…"

 

More than 500 drugs for rare diseases are in development  – Mirada Professional, June 6, 2016

"In addition, large laboratories benefit from the reduction of the period approval ten months compared to thirteen, and the high prices. EvaluatePharma consultancy estimates that the average cost per patient per year treated with orphan drugs was $ 111,820 in the US in 2014, compared with $ 23,331 for a conventional treatment..."

*Translated from Spanish

 

Oncology: Novartis-Eisai alliance to Afinitor and Lenvima  – Daily Health Industry, June 6, 2016

"The pharmaceutical company has in mind a growth for this drug: they are ongoing studies on several other tumor types, according to estimates of Eisai, will lead to a billion annual sales by 2020, more than twice compared to Evaluate forecasts Pharma which amounted to $ 424 million by 2019…"

*Translated from Italian

 

Valneva Forgets Pseudomonas Vaccine  – Seeking Alpha, June 7, 2016

"More data should be available in the coming months, but a spokesperson for Valneva told EP Vantage that the company expects to discontinue the program…"

 

Form 8-K Juno Therapeutics, Inc. For: Jun 07  – Street Insider, June 7, 2016

"Market size based on global sales forecast from EvaluatePharma in 2020. (2)Celgene, Takeda, Amgen Financial Reports 2015. (3)9 months ended December ..."

 

C4X Aims To Fix Big Pharma's Drug Discovery Problems  – Seeking Alpha, June 8, 2016

"A recent analysis by EP Vantage found that six of the top 10 drug companies derived less than 20% of their 2015 sales from products developed in-house; the industry is becoming ever more reliant on acquisitions for growth…"

 

GSK sets its sights on triple-combo-land with bumped-up COPD app  – FiercePharma, June 8, 2016

"We are not ... developing a triple combination for the time being," BI Chairman Andreas Barner told EvaluatePharma last year…"

 

Regain Pain For Alexion's Soliris  – Seeking Alpha, June 8, 2016

"Even so, chances of approval in myasthenia gravis are in doubt – and if it does not get the go-ahead it could be hard for Soliris to achieve its 2022 EvaluatePharma consensus sales forecast of $5.58bn…"

 

MIG AG: zwei weitreichende Portfoliounternehmen  – Finanzwelt, June 9, 2016

"EP Vantage etwa titelte einen Artikel mit „ASCO 2016 – Ganymed bewirbt sich für den Unicorn Titel mit Magenstudie"…"

 

Vantage Point - Patient-Reported Data Gain Traction In FDA Decisions – Seeking Alpha, June 9, 2016

"No matter how the US FDA deals with Sarepta Therapeutics' (NASDAQ:SRPT) Duchenne muscular dystrophy project eteplirsen, one potential solace is that because of fierce activism surrounding the project regulators might now be more attuned than ever to incorporating patient advocates' views into agency action."

 

No Bingo For Lingo  – Seeking Alpha, June 9, 2016

"The sellside seems to have been relatively cautious on opicinumab, as shown by EvaluatePharma’s consensus sales forecasts of just $323m in 2022; Leerink did not even include the anti-Lingo-1 MAb in its model, though at the height of the bull market Credit Suisse had suggested that the asset could be worth $10bn…"

 

Zimmer Biomet Shows Some Backbone With $1bn LDR Buy  – Seeking Alpha, June 9, 2016

"The company is currently forecast to be the sixth-largest player in spinal devices by 2022 sales, EvaluateMedTech’s consensus forecasts show, but the addition of LDR will buoy it to third, with revenues from these products of over $1.1bn…"

 

Sirukumab's Best-In-Class Promise Fades  – Seeking Alpha, June 10, 2016

"EvaluatePharma's sellside consensus pegs sirukumab as the bigger seller, with 2022 revenues of $949m versus $753m for sarilumab – but this could change if the J&J/Glaxo asset does not better AbbVie’s bestseller…"

 

Deal Watch May 2016  – PMLiVE, June 10, 2016

"A recent analysis through 2015 made by EvaluatePharma shows that six of the top ten pharma companies will derive less than 20% of drug sales from products that were developed from their own stable…"

 

L’inarrestabile crescita del mercato oncologico ($107bn) – Goinpharma, June 10, 2016

"Se si vanno a vedere i farmaci si osserva che saranno circa 20 le molecole che contribuiranno maggiormente a raggiungere i $150bn di fatturato e secondo EvaluatePharma tra queste vi sono: Herceptin e Avastin (Roche), Enbrel (Pfizer e Amgen), Januvia (Merck MSD) e Ordivo (BMS)…"

 

Therapy Focus - First-Line Lung Cancer Is An Opdivo Vs. Keytruda Showdown  – Seeking Alpha, June 10, 2016

"But competition in the NSCLC market looms, and a review by EP Vantage shows 23 phase III studies under way with PD-1/PD-L1 inhibitors…"

 

LifeSci Models Its New Behavior – Seeking Alpha, June 10, 2016

"Speaking to EP Vantage Mike Rice, a founding partner of LifeSci Advisors, is frank about his company’s past conduct…"

 

“Мировой фармацевтический рынок в 2015 году: «Возобновление бракосочетания слонов  – Pharm Reviews, June 13, 2016

“По оценкам международной аналитической компании «Evaluate Pharma», в 2015 году объем мирового фармацевтического рынка достиг 1 089 млрд $ США, что на 5% больше, чем в 2014 году (рисунок 1)...”

 

The top companies in med tech: 2015 revenue results – FierceMedicalDevices, June 14, 2016

"Med tech companies have found only one reliable way to boost sales--that's to buy them. The only players with sizable sales increases last year were driven by major acquisitions, according to data from Evaluate Medtech."

 

Ziarco Lacks Sparkle In Atopic Dermatitis – Seeking Alpha, June 14, 2016

"This does not faze Ziarco. Its chairman, Mike Grey, told EP Vantage that the company had the cash to get ZPL-389 ready for phase III in both atopic dermatitis and a second indication, psoriasis…"

 

UK biotech venture capital hit record high in 2015 with £489m raised, finds report  – Manufacturing Chemist, June 16, 2016

"The UK biotechnology sector continues to grow, raising an unprecedented £900m on the London Stock Exchange in 2015 and recording the highest level of venture finance in recent years, according to a new report compiled by the UK BioIndustry Association (BIA) in partnership with Evaluate and the London Stock Exchange (LSE)…"

 

Biotech is booming  – Cambridge News, June 16, 2016

"The UK biotechnology sector continues to build on the success of previous years, raising an unprecedented £900m on the London Stock Exchange in 2015 and recording the highest level of venture finance in recent years, according to the latest report Money, momentum and maturity: UK biotech financing and deals in 2015/16 compiled by the UK BioIndustry Association (BIA) in partnership with Evaluate and the London Stock Exchange…"

 

Big money questions remain on CARA  – Politico, June 21, 2016

"MedPAC’s recommendation to consolidate billing codes for Part B drugs with similar health effects could spark price competition, deter development of "me-too" drugs and may be more popular with lawmakers than other proposals circulating to change reimbursement for physician-administered drugs, EP Vantage explains…"

 

Jardiance Label Claim Is The Next Milestone For Booming SGLT2 Class  – Seeking Alpha, June 21, 2016

"Consensus forecasts reveal that great things are already expected – EvaluatePharma data show the SGLT2s becoming the third-biggest diabetes class in 2022, contributing two of the five biggest-selling brands that year (see tables below)…"

 

Big Pharma harvests far more from transplants than homegrown meds – FiercePharma, June 22, 2016

"According to EP Vantage's calculations, Allergan counts just 7% of its sales from in-house projects, and Roche's homegrown sales amount to just 8% ..."

*Also appeared on BioPharma Dive

 

Could label update for diabetes med Jardiance boost drug class? – BioPharma Dive, June 22, 2016

"Data for Johnson & Johnson's Invokana is expected in 2017 while AstraZeneca's Farxiga will have to wait until 2019, according to EP Vantage."

 

Tocagen Touts Two-Step Cancer Vaccine  – Seeking Alpha, June 22, 2016

"This is a disease without many options. The treatment has shown potential in many cancer types, Tocagen's chief executive, Harry Gruber, tells EP Vantage…"

 

Valuable Late-Stage Pipeline Sets 2017 Up For Some Big Events  – Seeking Alpha, June 23, 2016

"Assets worth $77.5bn are awaiting regulatory judgement while the phase III pipeline is worth $362bn, EvaluatePharma’s NPV data show…"

 

Analyse: Den globale pipeline er 3.700 mia. kr. Værd  – MedWatch, June 24, 2016

"Det viser en ny analyse fra Evaluate Pharma..."

 

R&D growth and new blockbusters predicted by report  – The Pharma Letter, June 24, 2016

"The EP Vantage Pharma & Biotech 2016 Preview, put together by a team of industry analysts, also predicts that Anglo-Swedish company AstraZeneca (LSE: AZN) will slip to the bottom of the top 10 biggest firms in the industry, and that Humira (adalimumab), an arthritis med marketed by the USA’s AbbVie (NYSE: ABBV), will remain pharma’s best-selling drug…"

 

Pharmaceutical Research: Big Pharma Prefers the "Semi" – Daily Health Industry, June 27, 2016

"Abbvie has a similar story. His medication by far best-selling Humira is that, as EP Vantage, arrived in the company's portfolio through acquisition of pharmaceuticals BASF…"

*Translated from Italian

 

GW Defies Brexit Blues With Second Epilepsy Win  – Seeking Alpha, June 27, 2016

"Chief executive Justin Gover told EP Vantage that detailed data from this and the second Lennox-Gastaut trial would be ready for presentation at the American Epilepsy Society meeting in December…"

 

Brexit Analysis - Top 10 U.K. Drugs  – Seeking Alpha, June 29, 2016

"EvaluatePharma’s European drug forecasts module shows that Bayer (OTCPK:BAYRY)/Regeneron’s (NASDAQ:REGN) Eylea will be the best seller in the UK in 2022, taking over from AbbVie’s (NYSE:ABBV) Humira, which was the top drug in 2015 (see tables below)…"

 

 

 

 May 2016

Xarelto, Xtandi surge toward Europe's best-selling ranks, with Opdivo close behind FiercePharma, May 2, 2016

"Also contributing to the difference could be differences in forecast methods, which in Europe depends on government and historical sales data and proprietary methodology, EP Vantage notes."

 

Regeneron Nips At Amgen And Pfizer's Heels In Pain Drug Race Seeking Alpha, May 3, 2016

"Tanezumab is the only anti-NGF project that has an EvaluatePharma consensus forecast – $105m in 2022 – although Leerink Research expects $400m for fasinumab in 2020…"

 

Bayer's Xarelto projected to become top-selling drug in Europe by 2022 BioPharma Dive, May 4, 2016

"According to a new report from EP Vantage, Bayer's Xarelto is set to become top drug by sales in Europe by 2022, with Astellas's Xtandi coming in second."

 

3 Medical Devices Stocks Set to Beat this Earnings Season Zacks.com, May 4, 2016

"A recent EvaluateMedTech World Preview claims that the medical device space is positioned for impressive growth in the near term…"

 

Medtronic's Insulin Pump Deal Shows Size Matters Seeking Alpha, May 5, 2016

"According to data compiled by EvaluateMedTech before the UnitedHealthcare deal, Medtronic was forecast to be the leading company in insulin pumps in 2022 ..."

 

Adavium Targets Brazil And Beyond Seeking Alpha, May 5, 2016

"... US and China [for private healthcare]," Fred Aslan, chief executive of Adavium Medical, tells EP Vantage. The company has seemingly come out of nowhere to..."

 

Ultragenyx Looks To Data From Its Biggest Projects Seeking Alpha, May 5, 2016

"UX007 is forecast to become Ultragenyx’s biggest product, with sales set to reach $642m by 2022, according to sellside consensus from EvaluatePharma, and an NPV of $1.1bn, 46% the company’s market cap..."

 

Tildrakizumab's Moment In The Sun Seeking Alpha, May 5, 2016

"... $144m in 2022 respectively, according to EvaluatePharma's consensus – tildrakizumab has fallen from analysts' radar since the Sun-Merck deal was signed…"

 

Achillion Combo Data And Agios Rare Disease Play Seeking Alpha, May 6, 2016

"EvaluatePharma’s sellside consensus predicts that ’348 will bring in 2022 sales of $250m, while there are currently no forecasts for ’519. This will likely change if Agios ends up plumping for the earlier-stage candidate…"

 

Clovis Waves White Flag On Rociletinib But Readies New Attack Seeking Alpha, May 6, 2016

"Signs that rucaparib has been rising in prominence can be seen in EvaluatePharma's sellside consensus – rociletinib's 2020 forecast has dropped from $800m..."

 

Nel 2022, quali saranno i farmaci più venduti in Europa? Pharmastar, May 8, 2016

"Nella classifica di Evaluate Pharma, il farmaco attualmente numero uno al mondo, Humira, non risulta nelle primissime posizioni, evidentemente a causa della parziale erosione delle vendite generata dai suoi biosimilari prevista negli anni a venire…"

 

Another look at news in week to May 6The Pharma Letter, May 8, 2016

 

Swimming against the tide in pharmaceutical industry The Korea Times, May 8, 2016

"The total volume of the global biopharmaceutical market is expected to grow 8.7 percent on average every year to reach $278 billion by 2020, according to market intelligence company EvaluatePharma…"

 

Vifor Bets On Portfolio Before Potential Split Seeking Alpha, May 9, 2016

"Speaking to EP Vantage at the time of the spinout, Søren Tulstrup, chief executive of Vifor, said: "If you want to finance the future growth of Vifor Pharma you..."

 

Medicines Co. sells off cardiovascular drugs to Italy's Chiesi BioPharmaDIVE, May 9, 2016 

"Evaluate Pharma forecasts these three drugs will bring in roughly $1.2 billion between now and 2022. If all sales milestones are hit, the deal could be worth a roughly equal value to that cash flow, Evaluate notes…"

 

Medicines Company Goes All In On Cholesterol Shot Seeking Alpha, May 9, 2016

"Assuming that milestones are hit and those savings are achieved, the transaction will be worth around $1.2bn to the Medicines Company, roughly what EvaluatePharma forecasts in combined sales for the three products over the same period…"

 

Cost is holding back breakthrough cholesterol drugs The Recorder, May 10, 2016

"... most analysts predict that Repatha and Praluent will generate combined annual sales of over $5 billion by 2020, according to polling by Evaluate Pharma…"

 

Allergan on course to file uterine fibroid drug next year PMLiVE, May 10, 2016

"A recent analysis by EvaluatePharma suggested the drug could become the biggest-selling drug for uterine fibroids with sales of nearly $520m by 2020…"

 

Incyte's European Invasion Seeking Alpha, May 11, 2016

"... epacadostat is one of two Incyte pipeline projects to which analysts have attached forecasts, with EvaluatePharma's consensus forecasting $373m in sales by..."

 

Therapy Focus - Testing Times For Cancer Vaccines Seeking Alpha, May 12, 2016

"But there is still much activity in the cancer vaccine field. A review by EP Vantage suggests that there are at least 12 commercial cancer vaccines in phase III development, most of which are ex vivo modified autologous cell-based therapies like Provenge, and thus have the most complicated manufacturing economics…"

 

La top ten dei blockbuster 2016 Daily Health Industry, May 13, 2016

"L’agenzia statunitense EvaluatePharma ha stilato una classifica dei probabili blockbuster 2016 in campo farmaceutico, con stime di vendita al 2020…"

 

NASH Data From Tobira And Karyopharm's Myeloma Trial Seeking Alpha , May 13, 2016

"2022 worldwide sales consensus for selinexor sits at $439m, according to EvaluatePharma…"

 

Safety Worries Loom For Bayer's Adempas Seeking Alpha , May 13, 2016

"To say that Bayer’s (OTCPK:BAYRY) hypertension drug Adempas is a disappointment is an understatement. The product, once expected to bring in $870m by 2018, now has a 2022 forecast of just $459m according to EvaluatePharma sellside consensus…"

 

AZ gets orphan status for selumetinib in thyroid cancer PMLiVE, May 13, 2016

"Orphan drugs accounted for $54bn in sales in the US last year and are expected to reach $60bn in 2016, according to EvaluatePharma data…"

 

Look back on pharma news May 9-13 The Pharma Letter May 15, 2016

"EP Vantage also commented on the failure of NewLink Genetics’ Phase III failure of algenpantucel-L, saying it is not only a blow to the company, it also dashes hopes of getting a new pancreatic cancer therapy approved any time soon."

 

Hemco Gage taps medical device, aerospace sectors for growth MiBiz, May 15, 2016

"The global medical device industry is expected to grow 4.4 percent a year after reaching a projected $384 billion in annual sales in 2015, according to a report from EvaluateMedTech…"

 

AstraZeneca plc, Merck, AbbVie Inc: Can Generics pose a Threat?Business Finance News, May 16, 2016

"According to the statistics provided by the Evaluate Pharma, approximately $120 billion is lost due to patent expirations from 2009-2014. It is expected that $215 billion are at stake as the majority of the drugs including some of the blockbusters like Humira will lose their patents in the future…"

 

Pfizer Looks Elsewhere In Derm, Finds Anacor Seeking Alpha, May 17, 2016

"EvaluatePharma forecasts the former to pull in $66m in royalties in 2022, while crisaborole should earn $1.8bn – Pfizer estimated peak sales could reach $2bn…"

 

New patent threat looms for AbbVie's blockbuster Humira BioPharmaDIVE, May 18, 2016

"AbbVie's composoition of matter patents on Humira will expire in December of this year, but AbbVie CEO Rick Gonzalez believes the company can stave off biosimilar compeititon until 2022, according to EP Vantage…"

 

How to Recruit the Best Medical Sales Reps After M&A MedReps.com, May 18, 2016

"In medtech, the total value of mergers reached $127 billion in 2015, according to data from EP Vantage…"

 

Setbacks Still Outweigh Successes In Heart Failure Seeking Alpha, May 18, 2016

"However, Cardiorentis has been rather coy about the trial’s outcome, especially when it withdrew – at the last moment – from making a formal presentation at the American College of Cardiology in early April. As a private entity, Cardiorentis can choose how and when to disclose its data. The company did not return calls from EP Vantage to discuss its upcoming data today…"

 

Can Adempas meet Bayer's growth expectations after a canceled trial? FiercePharma, May 18, 2016

"The move scuttled hopes of a label expansion down the line, which could have swelled sales that right now need a boost. EvaluatePharma now predicts Adempas will rack up just $459 million in 2022 sales--a far cry from the $870 million analysts once expected to see by 2018, EP Vantage notes..."

 

As takeover talks drag on, Baxalta staff find themselves in merger limbo STAT, May 18, 2016

"But, as industry veterans can attest, this is all part of the game in biopharma. More than 250 drug companies changed hands last year, according to analysis firm Evaluate Pharma, and a decline in biotech share prices has some analysts predicting another supermarket sweep in 2016…"

 

Novartis First To Make Pre-Asco Splash Seeking Alpha, May 18, 2016

"EvaluatePharma's consensus forecasts Ibrance sales of $5.3bn in 2022, suggesting that its first-mover advantage will allow it to take a majority of the revenue..."

 

Lynparza Puts A Small Dent In Parp Inhibitor Optimism Seeking Alpha, May 18, 2016

"The sellside expects Lyparza to bring in sales of $834m in 2022, entirely in ovarian cancer, according to EvaluatePharma consensus…"

 

Oral Insulin Could Be Fools' Gold Seeking Alpha, May 19, 2016

"Novo Nordisk seems to be the most active company in this field, with one asset in phase II and another in phase I. However, it also has four abandoned projects to its name, according to EvaluatePharma…"

 

Asco Preview - 2 Directions For Novel Small-Molecule Classes Seeking Alpha, May 19, 2016

"... a less differentiated profile than we'd hoped" in the Monarch 1 interim findings – EvaluatePharma's consensus of sellside analysts forecasts $1.8bn in 2022…"

 

Latest Indication For Soliris And U.S. Regulators Decide On ZS-9 Seeking Alpha, May 19, 2016

"According to consensus sales forecasts from EvaluatePharma they are expected to more than double to $5.6bn by 2022. It is marketed for paroxysmal nocturnal..."

 

The Evolving Biosimilars Market: 2016 Expected to Be a Pivotal Year Pharmaceutical Processing, May 19, 2016

"Cumulatively, these respective reference products generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma…"

 

Look back on pharma news May 16-20 The Pharma Letter, May 22, 2016

"Commenting on US pharma giant Pfizer’s latest M&A move last week, EP Vantage, the editorial arm of the Evaluate group, recalled that Pfizer lost its chance at scooping up the number four player in dermatology when its $160 billion Allergan acquisition fell apart under US government pressure. .."

 

Despite recent R&D setbacks, Lilly aims to launch 20 new drugs by 2023 BioPharmaDIVE, May 24, 2016

"Still, Lilly has continued to spend significant cash on drug development, investing 24% of revenues to R&D in 2015 - the third highest mark in the industry, according to EP Vantage…"

 

Novartis breast cancer drug proves efficacy, trial stopped early Seeking Alpha, May 24, 2016

"Evaluate Pharma sees Ibrance staying in the lead for some time and forecasts $5.3 billion in global revenues by 2022. And if Lilly's development plans with abemaciclib come to fruition, Pfizer and Novartis could face additional competition. All of this is good news for patients, as combo therapies have shown greater efficacy in treating breast cancer…"

 

In-House Projects An Ever-Thinner Slice Of Sales For Big Pharma Seeking Alpha, May 24, 2016

"An analysis of EvaluatePharma data through 2015 shows that six of the top 10 drugmakers will derive less than 20% of drug sales from products developed in..."

 

At Last Some Good News For Entresto Seeking Alpha, May 24, 2016

"In spite of the slow start, the Jefferies analysts expect Entresto sales of just under $4bn in 2020, while sellside consensus, as computed by EvaluatePharma…"

 

Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023 Fortune, May 24, 2016

"An outsize share of Lilly’s revenues have flowed from drugs that are more than 10 years old, according to life sciences analytics firm EP Vantage. …"

 

Xarelto Litigation Progresses Amid Growing Sales DrugWatch, May 26, 2016

"Xarelto is still the most prescribed drug in its class in the U.S. and will remain the top drug well into 2022 in Europe, EvaluatePharma analysts report…"

 

UK team develops smartphone-based in-vitro test system The Engineer, May 27, 2016

"EvaluateMedTech estimates the total worldwide market for IVD devices to be worth around $50bn per year, and is predicted to grow to $67bn by 2020…"

 

New Cancer Treatment Law Passes as Georgia Lawmakers Play Doctor Heartland, May 31, 2016

"FDA fast-tracked Keytruda for approval in September 2014. Pharmaceuticals analyst EvaluatePharma expects it to be the 14th top-selling product in the United States by 2020…"

 

Look back on Pharma news May 23-27The Pharma Letter, May 31, 2016

"But while the takeover announcement highlighted the 60% premium that this represents to last week’s share price, few long-term investors will be sitting on a profit, according to EP Vantage, the editorial arm of the Evaluate group…"

 

 April 2016

Panorama de la industria de tecnologías para ortopedia – El Hospital, April, 2016

"Johnson & Johnson (Estados Unidos) es líder en la industria de tecnología médica y continuaría en el primer lugar entre las compañías de la industria ortopédicaen los próximos años por medio de su filial DePuy Synthes. De acuerdo con las estimaciones publicadas por EvaluateMedTech, esta firma crecerá con una TCAC del 2,4% y alcanzará ventas por 10,5 mil millones de dólares en 2020…"

 

Alder Grows With Migraine Success Seeking Alpha, April 1, 2016

"But even comparing the latest results with other chronic migraine trials can be problematic, noted Evercore ISI analyst Umer Raffat, who lined ALD403 up against Teva’s TEV-48125 – the only other CGRP blocker with phase II results in chronic disease and the drug to beat if EvaluatePharma consensus forecasts are anything to go by."

 

Price of success: Medivation reportedly hires JP Morgan to help fend off deal-hungry buyers – BioPharmaDIVE, April 1, 2016

"Xtandi was approved in 2012 for second line treatment of a specific form of prostate cancer (called mCRPC) but the FDA has since expanded its label. EvaluatePharma projects sales of $1.87 billion this year, with revenues of $4.78 billion by 2020. "

 

Dupilumab Grabs Atopic Dermatitis Head Start Seeking Alpha, April 1, 2016

"Regeneron and Sanofi should have a couple of years' head start over competitors, helping dupilumab achieve 2020 sales of $2.5bn, EvaluatePharma..."

 

Another look at the news in the week to April 1 The Pharma Letter, April 3, 2016

"... be spinning after trying to understand the various data iterations from this complicated study, according to EP Vantage, the editorial arm of the Evaluate group…"

 

In phase 3 collaboration, Merck and Pfizer testing PDL1/TKI combo BioPharmaDIVE, April 5, 2016

"Their clinical and commercial success is spurring a flood of combination studies. EP Vantage estimates roughly a third of these studies combine PD1/PD-L1 inhibitors with small molecules like Inlyta…"

 

Janssen follows AZ to develop PARP inhibitor in prostate cancer Pharmaphorum, April 6, 2016

"EvaluatePharma last year said 2020 consensus forecasts for niraparib stand at $499 million. Sales of Lynparza, already approved in the US and EU in ovarian cancer, were forecast to be $566 million…"

 

Sosei Deal Marks Allergan's Return To Business As Usual Seeking Alpha, April 7, 2016

"Its initial focus is Alzheimer’s disease, Heptares’s chief executive, Malcolm Weir, told EP Vantage, and there is potential to go into additional CNS indications."

 

After Alzheimer's drug passes safety review, AstraZeneca and Lilly push into Phase 3 – BioPharmaDIVE, April 8, 2016

"So far, Merck appears furthest along, expecting a primary completion date for its Epoch study in July 2017, according to EP Vantage…"

 

Shock Approval For Abiomed But Big Test To Come Seeking Alpha, April 8, 2016

"Current consensus sales forecasts compiled by EvaluateMedTech have the company growing at 24% annually to 2020…"

 

Will Funding Woes Doom The Next Generation Of Medtech Innovators? Med Device Online , April 8, 2016

" In March, Evaluate Ltd. released its annual report, Medtech 2015 in Review. The report contains global market analysis and insights related to the financial performance of the medical device and diagnostic industry. "

 

Juno Therapeutics and WuXi set up new biotech in China The Pharma Letter, April 9, 2016

" And, while few might realise this, the Chinese CAR-T market is actually relatively competitive, commented EP Vantage, the editorial arm of the Evaluate group."

 

Another look at the news in week to April 8 The Pharma Letter, April 9, 2016

"... Amgen's biosimilar form of the world's bestselling drug, AbbVie's Humira, is under consideration by the Food and Drug Administration, comments EP Vantage..."

 

Will Shire PLC and other Acquire Biogen Inc Hemophilia Portfolio? – Business Finance News , April 10, 2016

"EvaluatePharma statistics showed that the therapeutic market of hemophilia is expected to grow at $176 billion by 2020..."

 

Shire, Bayer Can Eye Biogen’s Hemophilia Assets For Acquisition – BidnessEtc, April 11, 2016

"According to research by EvaluatePharma, the rare disease drug market can grow by more than 60% in the next five years to $176 billion. Hence, there may be many takers for Biogen’s hemophilia assets if they ever go up on sale…"

 

Interview - Allergy Therapeutics Sniffs Out Second Chance – Seeking Alpha, April 12, 2016

"Allergy's chief executive, Manuel Llobet, tells EP Vantage that, being subcutaneous, Pollinex Quattro “will have a really fast penetration"."

 

Venetoclax Approval Could Open Doors For AbbVie Seeking Alpha, April 13, 2016

"If these can be allayed and the drug expanded into broader uses, sales could hit $1.8bn by 2020, according to EvaluatePharma’s consensus of sellside forecasts…"

 

FDA Finds Epigenomics Appealing Seeking Alpha, April 13, 2016

‘"We had a discussion with the FDA and it turns out they were not quite comfortable yet with the data we had provided, but they didn’t really know what else to ask for," Thomas Taapken, the group’s chief executive, tells EP Vantage…’"

 

Number of Mass. medical device firms doubles in 20 years – Boston Business Journal (blog), April 13, 2016

"Tom Sommer, president of the association, also pointed to more FDA approvals in 2015 than in the past decade, and a 55 percent increase over 2014, according to data gathered by Evaluate MedTech. "

 

Biosimilars: A New Wave of Generic Drugs NASDAQ, April 14, 2016

"According to estimates by EvaluatePharma, biologics with aggregate US sales of $79 billion will lose patent protection between 2013 and 2018…"

 

Interview - U.K. Cell Therapy Minnow Squares Up To Juno Seeking Alpha, April 14, 2016

"The other is from the Fred Hutchinson center, and is now licensed to none other than Juno (NASDAQ:JUNO). ‘The key is having a T cell that recognizes the target antigen with sufficient avidity that it responds, but isn’t of so high affinity that it binds to lower-level antigens on normal cells,’ University College London’s Professor Emma Morris, the UK trial’s chief investigator, tells EP Vantage…"

 

Race between Novartis and Pfizer continues DAZ, April 15, 2016

"After an investigation of the analyst firm Evaluate Pharma of Pfizer Allergan sales had taken together the current year probably reached $ 70.4 billion. The Swiss competitor Novartis would lagged with expected $ 44.5 billion, however clearly defeated. But even without the mega merger could Pfizer this year, the T recapture opposition in the pharmaceutical world . According to Evaluate Pharma Pfizer sales expected in 2016 will be $ 48 billion while it brings to Novartis expected $ 44.5 billion…"

 

Another look at the news in week to April 15 – The Pharma Letter, April 17, 2016

"If these can be allayed and the drug expanded into broader uses, sales could hit $1.8 billion by 2020, according to EvaluatePharma's consensus of sellside…"

 

Review of NCI facilities halts patient enrollment in Kite T-cell studies – BioPharmaDIVE, April 17, 2016

"According to EP Vantage, enrollment had been halted on April 12 but Kite did not release details until Saturday…"

 

Johnson & Johnson In A Quandary Seeking Alpha, April 18, 2016

"... fiscals since 2013, JNJ has lost 12% in a market that's actually growing by 4.4% and expected to reach $440 billion by 2018, according to EvaluatePharma…"

 

Interview - Despite The Many Unknowns Celgene Banks On CAR-T Take-Off Seeking Alpha, April 18, 2016

"In the next couple of years the US biotech will look to put more money where its mouth is, as decisions on manufacturing investments approach. "At the very start… we said we wanted to see at least two truly breakthrough therapies come out of this collaboration," George Golumbeski, head of business development and alliance management, told EP Vantage, adding that these would likely come from solid tumour targets beyond the low-hanging fruit of the CD19 antigen…"

 

Opdivo gives head and neck cancer patients a shot at 12-month survival FiercePharma, April 20, 2016

"First approved in 2014, both of the meds are forecast by EvaluatePharma to be among the top 20 best-selling drugs in the world by 2020…"

 

Interview - Boehringer Hopes Jardiance Can Be As Big As Statins – Seeking Alpha, April 20, 2016

"Allan Hillgrove, head of the group's prescription medicines business, was more cautious, telling EP Vantage: “Will it be as large as statins? Let's wait and see."

 

Can Humira Still Dominate In 2022? Seeking Alpha, April 21, 2016

"The forecast best-selling drug in 2022 might come as a surprise to some: AbbVie’s (NYSE:ABBV) veteran Humira is set to regain the top spot, according to extended EvaluatePharma consensus data (see tables below)…"

 

Interview - $29m For Prototype-Stage G-Therapeutics Seeking Alpha, April 21, 2016

"We will start a very small pilot study this year with a research prototype that is a combination of our own software and some components that we got from another company," its chief executive, Sjaak Deckers, tells EP Vantage…"

 

AbbVie Goes Preclinical In Pursuit Of Cancer Payoff Seeking Alpha, April 22, 2016

"Until last year AbbVie recorded less than $1bn a year in oncology sales, but the acquisition of Pharmacyclics brought half of the economic interest of the blockbuster Imbruvica, and the approved drug Venclexta and phase III project veliparib promise to add $3bn to the top line by 2022, according to EvaluatePharma’s consensus…"

 

Speculation Juno (JUNO) Could Buy Bellicum Pharma (BLCM) – Street Insider, April 22, 2016

"Biotech reporter Jacob Plieth from EP Vantage speculates Juno Therapeutics (NASDAQ: JUNO) could acquire Bellicum Pharma (NASDAQ: BLCM). From the report: One of these is a suicide gene that can be incorporated into the T cells to destroy them in the event of serious toxicity. In an interview with EP Vantage at this week’s AACR meeting Mr Levitsky spelled out his desire to own something better than Juno’s current suicide switch, raising an interesting business development question: should Juno buy Bellicum?"

 

Juno's Search For Bells And Whistles – Seeking Alpha, April 22, 2016

"In an interview with EP Vantage at this week’s AACR meeting Mr. Levitsky spelled out his desire to own something better than Juno’s current suicide switch, raising an interesting business development question: should Juno buy Bellicum (NASDAQ:BLCM)?"

 

Boosting pipeline, AbbVie inks two deals for preclinical cancer drugs – BioPharmaDIVE, April 22, 2016

"Although some of the drug's patent protection is slated to expire this year, AbbVie CEO Rick Gonzalez thinks it can keep biosimilars off the market until 2022, according to EP Vantage…"

 

Another look at the news in week to April 22 – The Pharma Letter, April 22, 2016

"... rejected because it lacked a control group, setting the company back by at least two years, noted EP Vantage, the editorial arm of the Evaluate group…"

 

Breakthrough cholesterol drugs fizzle amid price pushback Athens Online, April 23, 2016

"While many have slashed short-term estimates, most analysts predict that Repatha and Praluent will generate combined annual sales of over $5 billion by 2020, according to polling by Evaluate Pharma…"

 

US FDA grants Orphan Drug designation to DelMar Pharma's VAL-083 to treat ovarian cancer – Pharmabiz, April 25, 2016

"According to Evaluate Pharma, the market for ovarian cancer therapies is expected to be approximately $570 million in 2016 and is projected grow to more than $3.5 billion in 2022…"

 

Medical device investors: is this an oxymoron in the making? – Medtech Engine, April 26, 2016

"It’s a view confirmed by industry figures. In its 2015 Medtech Half-Year Review, EP Vantage noted that only 287 early-stage medtech companies managed to secure equity investment across the year as a whole, 30 per cent down on 2014…"

 

Never mind the chill, biotech IPO winter will pass Pharmaphorum, April 27, 2016

"Figures from EvaluatePharma show that private drug developers raised a staggering $8.68 billion, up 19% on the previous year and the biggest annual total since at least 2007…"

 

GSK’s new vax unit defies slow growth concerns with sales, profit gains FiercePharma, April 27, 2016

"An EvaluatePharma report last year said that the top four players by 2020 - a group that includes Merck ($MRK), Pfizer ($PFE) and Sanofi ($SNY) as well - will be within one percentage point of market share that year…"

 

Americans consume vast majority of the world's opioids CNBC, April 27, 2016

"Based on 2015 sales, the top five opioid products were made by Purdue Pharma, Johnson & Johnson, Insys Therapeutics, Mylan and Depomed, according to EvaluatePharma, a life sciences market intelligence firm, which tracks sales. Based on 2015 sales, the top five opioid products were made by Purdue Pharma, Johnson & Johnson, Insys Therapeutics, Mylan and Depomed, according to EvaluatePharma, a life sciences market intelligence firm, which tracks sales…"

 

Sanofi veut racheter l'américain Medivation spécialisée en oncologie La Croix, April 28, 2016

"Le marché mondial de l'oncologie pesait quelque 80,7 milliards de dollars l'an dernier. Il pourrait atteindre près de 120 milliards de dollars en 2020, soit un taux de croissance annuel moyen de 8%, selon une récente étude du cabinet d'analyses EvaluatePharma…"

 

Sanofi wants to buy American Medivation specialized in oncology Liberation, April 28, 2016

"The global oncology market weighed about 80.7 billion dollars last year. It could reach nearly $ 120 billion in 2020, an average annual growth rate of 8%, according to a recent research firm EvaluatePharma analyzes..."

*Also appeared on lejdc.fr

 

As new drugs take hold, Lilly ramps up R&D spend BioPharmaDIVE, April 28, 2016

"Indeed, Lilly was the third highest spender on R&D in 2015 based on percent of sales, according to EP Vantage…"

 

Samsung Biologics plans IPO this year, seen worth as much as $2.6 billion – Reuters, April 28, 2016

"The global market for biotech drugs is expected to grow to $278 billion in 2020, up 52 percent from 2015 levels, according to data provider Evaluate Pharma, as aging populations in many countries fuel demand for medicine…"

 

UPDATED: Samsung BioLogics looking to tap IPO for as much as $2.6B this year  – FiercePharma, April 28, 2016

"Reuters, citing data service Evaluate Pharma, said the market for biologic drugs is slated to expand 52% to $278 billion by 2020 from 2015 levels as new products emerge from R&D and clinical efforts…"

 

Блокбастеры, компании-лидеры и перспективные новинки: подводим итоги 2015 г. Apteka.ua, April 28, 2016

"Некоторым из них специалисты компании «Evaluate Pharma» пророчат судьбу блокбастеров через 5 лет после лонча. Внимания также заслуживают перспективные разработки прошлого года, которые предположительно выйдут на фармацевтический рынок или уже вышли в текущем году…”

 

Shifting Prostate Landscape Underpins Sanofi's Medivation Offer – Seeking Alpha, April 29, 2016

"However, Evaluate Pharma consensus data suggest that global Xtandi sales will this year surpass those of Zytiga for the first time, and continue to grow strongly..."

 

Fight against cancer: Sanofi wants to crunch the California Medivation Parkinson’s Challenges, April 29, 2016

"According to the firm Evaluate Pharma, sales of anti-cancer treatments rose by 11.6% per year…"

 

FDA OKs a breakthrough antipsychotic from Acadia for Parkinson’s – FiercePharma, April 30, 2016

"A recent roundup of top drugs in the clinic by Evaluate Pharma pegged potential 2020 sales of $841 million for Nuplazid, though several analysts expect it to break into the $1 billion-plus club in the next 5 years…"

 

 March 2016

Rx for Growth? Market Realist, March 1, 2016

"As we’ve seen, generics make up more than 88% of total prescriptions in the United States but only 28% of total drug costs. The rise of generics has indeed been monumental. According to data from Evaluate Pharma, global generic drug sales rose 7% to a massive $74.2 billion in 2014. $61.7 billion (or 83.1%) of total sales came from the top 20 generics producers…"

 

Exelixis Snares Ipsen As Euro Cabo Partner Seeking Alpha, March 2, 2016

"In an interview on the sidelines of the JP Morgan conference in January, chief executive Mike Morrissey told EP Vantage the group had been eager for a partner..."

 

Maladies rares - Les orphelins de la médecine Agoravox, March 2, 2016

"Mais puisqu'il est question de rentabilité et des profits des laboratoires pharmaceutiques, d'après le cabinet EvaluatePharma, le marché estimé actuellement à 100 milliards de dollars devrait dépasser les 175 milliards en 2020… "

 

Kite, Juno ramping up commercial manufacturing for CAR-T therapies BioPharma Dive, March 3, 2016

“As the EP Vantage report points out, the focus on getting commercial manufacturing processes up and running will burn a substantial amount of cash. Both Kite and Juno have bulked up on cash to meet future demands.”

 

「抗体薬、新技術で開拓  日本勢、欧米勢に対抗」(日本経済新聞朝刊) Nikkei Biotech Online, March 3, 2016 

 

Risk of major adverse cardiovascular events significantly reduced with Victoza The Pharma Letter, March 4, 2016

"... seller back onto the formulary of Express Scripts, the largest US pharmacy benefit manager, according to EP Vantage, the editorial arm of the Evaluate Group…"

 

Another look at Week to March 4 news  – The Pharma Letter, March 5, 2016

“... will have one less immediate threat with Roche's announcement that rival lebrikizumab failed one of its two pivotal trials, commented EP Vantage, ...”

 

Прогноз — дело тонкое  Pharmvestnik, March 7, 2016

“Эксперты EvaluatePharma составили перечень потенциальных лидеров продаж в 2020 r…”

 

FDA accepts new Keytruda data, opening door for wider indication  BioPharma Dive, March 9, 2016

“Keytruda is also used more often than Opdivo in combination studies pairing it with another drug. According to data from EP Vantage, there are over 50 combo studies using Keytruda compared to 40 for Opdivo. Many of those studies pair Keytruda with a small molecule or chemotherapy."

 

Sanofi's sarilumab bests blockbuster Humira in Phase 3 study BioPharma Dive, March 11, 2016

“But, according to EP Vantage, AbbVie is confident it can resist biosimilar competition undercutting Humira until 2022 and predicts $18 billion plus in 2020 sales.”

 

Sanofi and Regeneron's would-be blockbuster tops Humira in arthritis FierceBiotech, March 11, 2016

"The treatment has long been pegged as a blockbuster in waiting, with 2020 sales predicted to hit $1.8 billion, according to analyst estimates compiled by EvaluatePharma…"

 

UPDATED: Pfizer's Prevenar 13 patent challenged in India as MSF continues its price fight  FiercePharma, March 11, 2016

"That was expected to add about $2 billion in sales. It is projected by EvaluatePharma to be the fifth best-selling drug in the world in 2020 at $6.9 billion. GSK had 2015 sales of about $548 million for Synflorix…"

 

Another look at news in the Week to March 11 The Pharma Letter, March 13, 2016

“... with the company blaming better than expected survival among control patients, commented EP Vantage, the editorial arm of the Evaluate group.”

 

Zydelig 'dead in the water' after trial deaths force Gilead to stop frontline studies FiercePharma, March 15, 2016

"Several recent--and very successful--cancer launches delivered far less, so blockbuster sales estimates were common among analysts; EvaluatePharma put Zydelig sales at $1.2 billion by 2020, and some analysts went as far as to predict $1.5 billion by 2017. The drug brought in $132 million last year…"

 

Managed Health Care Associates, Inc. (MHA) Partners with Evaluate Ltd to Provide Streamlined Access to Key Pharmaceutical Pipeline and Business IntelligenceIT Business Net, March 15, 2016

“Managed Health Care Associates, Inc. (MHA), a leading health care services and technology company focused on the alternate site health care provider marketplace, today announces the launch of a collaboration with Evaluate Ltd, a life science market intelligence and forecasting leader.”

 

EP Vantage Releases Its Annual Analysis of Pharma & Biotech and Medtech Sector Performance One News Page, March 16, 2016

“These findings and more were released today as part of the Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate Ltd.”

 

2015 was the year of the biotech VC mega-round, according to new report Boston Business Journal, March 16, 2016

“..according to an analysis by EP Vantage, more of that went to gargantuan mega-rounds than ever before (…) The life sciences market intelligence firm today put out its Pharma & Biotech 2015 in Review report on trends in that sector..”

 

Early-stage biotech funding at risk from drying well FierceBiotech, March 16, 2016

"This is according to the annual Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports by EP Vantage, which were published this week…

 

More Sola Uncertainty Sends Lilly Down Seeking Alpha, March 16, 2016

"In spite of the low chance of approval, however, the Leerink analysts predict risk-adjusted 2026 sales of around $1.5bn- showing that while sola is a gamble, the rewards will be rich if it pays off. The drug is still, perhaps unbelievably, Lilly’s top pipeline prospect, with EvaluatePharma consensus putting 2020 revenues at $1.39bn.."

 

Five things you need to know today, and hide the children, it's St. Patrick's Day in BostonBoston Business Journal, March 17, 2016

“…than any other year in the past decade, but according to an analysis by EP Vantage, more of that went to gargantuan mega-rounds than ever before.”

 

Future innovation at risk as venture capital dries up for early-stage The Pharma Letter, March 17, 2016

“These findings and more have been released as part of the Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports by EP Vantage...”

 

Biotech venture performance in 2015: Huge financings, few rounds MedCity News, March 17, 2016

“The biotech investment climate sank into deep insecurity by the close of 2015, as shown in EP Vantage‘s new “Pharma & Biotech 2015 in Review” report.”

 

You'll Never Guess Which Pharma Likely Owns 40% of 2016's New Blockbusters The Motley Fool, March 19, 2016

"At least, so say numbers released by research firm EvaluatePharma. Those numbers identify 2016's top ten new drugs in peak projected sales. Forecasts for those new drugs total a combined $16.4 billion in peak annual revenue…"

 

Another look at the news in Week to March 18 The Pharma Letter, March 20, 2016

“EP Vantage, the editorial arm of the Evaluate group, added that GW Pharmaceuticals' doubling in valuation was a remarkable result given that the ...”

   

Mögliche Blockbuster in 2016 Goinpharma, March 20, 2016

"Gemäß EvaluatePharma hat Roche das Potential, Medikamente auf den Markt zu bringen, die die drei ersten Plätze der Top Ten-Produkte auf der Liste der von der FDA dieses Jahr zugelassenen Medikamente einzunehmen, in Bezug auf das Umsatzvolumen im Jahr 2016…"

   

L’alliance Sanofi-Google et l’ère de la médecine 3.0 Blogpolyfinances, March 22, 2016

"Evaluate Pharma évalue que les retombées totales de la vente de produits contre le diabète pour les pharmaceutiques se sont chiffrées à 41G $US en 2014 et qu’elles s’élèveraient à 60G $US en 2020. (Hecketsweiler, 2015) Pour Sanofi et son insuline vedette Lantus, les ventes étaient de 6G $US en 2014, mais son brevet vient d’arriver à échéance; son successeur, Toujeo, n’inspire pas la même confiance…"

   

A Lawsuit Comparison Of Pradaxa And Xarelto Digital Journal, March 22, 2016

"Most lawsuits allege that Xarelto caused uncontrollable internal bleeding resulting in death or serious injury. Despite thousands of lawsuits, Xarelto is anticipated to be the 19th best selling drug in the world and will generate 3.7 billion US Dollars in sales by 2018, which is up from the $596 million it generated in 2012, according to EvaluatePharma in its World Preview…"

   

Zacks Industry Outlook Highlights: Bayer, Abbott Laboratories, Roche Holding, Medtronic and DENTSPLY International Nasdaq, March 23, 2016

"In Vitro Diagnostics to dominate: According to a survey by EvaluateMedTech World Preview, IVD is expected to emerge as the sector leader by 2020 (14% of the total medical device market) with sales of $71.6 billion, reflecting annual growth of 6.1%. Roche Holding AG ( RHHBY ) is expected to lead this space with a 17% market share and sales of $12.20 billion by 2020…"

   

Corvus offers IPO at a discount as headwinds persist   FierceBiotech, March 23, 2016

"Although the IPO window is not hermetically sealed, you better have outstanding insider support to get an IPO away in the U.S.," he recently told analysts at EP Vantage.”

 

Roche CEO Schwan beats Novartis chief with $12.3M in 2015 pay, but U.S. companies shell out more   FiercePharma, March 24, 2016

"The company anticipates two big drug approvals--multiple sclerosis med ocrelizumab and immuno-oncology treatment atezolizumab--that EvaluatePharma pegs at $2.5 billion and $2.8 billion in 2020 sales, respectively. A leukemia treatment co-developed with AbbVie, Venetoclax, is also in line for FDA approval this year, with sales expectations of more than $1.5 billion by 2020…"

*Also appeared on - Pharmacodia

 

Endeavouring to Establish Europe’s Largest MedTech Fund    Labiotech.eu, March 24, 2016

"The 2015 Evaluate Pharma projection for the World Medtech markets predicts BIG growth, in the billions. (Source: EvaluateMedTech 2015 World Preview Report / Evaluate Pharma)…"

 

Upcoming Events - Celyad And CSL Shoot For The Heart   Seeking Alpha, March 25, 2016

"Perhaps illustrating caution in the sector, there is currently no sell-side consensus forecast for C-Cure in EvaluatePharma, unusual for a phase III project. Edison analysts estimate the probability of success for Chart-1 at 45%..."

 

Roche alla riscossa: dei 10 blockbuster del 2016, i primi 3 sono suoi   Pharmastar, March 30, 2016

"Secondo la società di ricerche di mercato EvaluatePharma, dei tre farmaci blockbuster in testa alla classifica, due sono farmaci oncologici, atezolizumab e venetoclax, ma la superstar del 2016 sarà ocrelizumab indicato per il trattamento della sclerosi multipla…"

 

Defitelio Highlights A Regulatory Fault Line   Seeking Alpha, March 31, 2016

"Defitelio is not alone in having scored such an accolade, and a search of EvaluatePharma reveals some 80 projects that have secured the green light in the EU ..."

 

With deal scouts knocking, Medivation hires JPMorgan to man the door    FiercePharma, March 31, 2016

"That's one reason why Medivation is a perennial favorite on market watchers' lists of buyout targets. With Xtandi on a path to blockbuster land, Medivation would give any buyer an immediate sales boost. The company will share the Xtandi wealth with marketing partner Astellas, but EvaluatePharma projects sales of $1.87 billion this year rising to $4.78 billion in 2020--plenty to go around…"

 

Roche sugli scudi: suoi i primi tre posti nella top ten dei blockbuster 2016    Rif Day, March 31, 2016

"Secondo le previsioni di EvaluatePharma, tutti e tre i farmaci, una volta che il loro lancio sarà completato, genereranno un fatturato annuo complessivo pari a 6,6 miliardi dollari, il 40% delle vendite totali generate dai 10 blockbuster che verranno lanciati nel 2016…"

 

 February 2016

 

Meet the CEO of Europe’s Leading Microbiome Biotech – The Labiotech.eu, February 3, 2016

“The overall Crohn’s Disease market is projected to increase from approximately $3.8 billion in 2011 to $5.6Bn (€5.1Bn) by 2021, so this specialty GI category is growing faster than any other therapeutic area according to Evaluate Pharma (2014).”

 

FDA panel backs game-changing cognitive claim for Lundbeck antidepressant Brintellix – FiercePharma, February 4, 2016

"But so far, Brintellix has not exactly been living up to its blockbuster hype. The drug brought in $28.4 million in 2014 sales, much lower than the $271 million predicted by EvaluatePharma. Brintellix sales for the first 9 months of 2015 rang in at $62 million.”

 

Lundbeck wins key FDA backing for expanding depression drug Brintellix's label – BioPharmaDIVE, February 5, 2016

"There were high hopes for Brintellix when it was approved two years ago, but sales have disappointed. In 2014, overall sales were $28.4 million, falling short of the $271 million EvaluatePharma predicted for that year...”

 

Last week's news in review The Pharma Letter, February 6, 2016

“Back in September Abbott told EP Vantage it was interested in large acquisitions, and six months later a $5.8 billion deal has arrived.”

 

Therapy Focus- Phase III Proves Tough For IPF Seeking Alpha, February 9, 2016

“The launches of Esbriet and Ofev caused a “seismic change” in the field of IPF, Dr Toby Maher, a leading specialist in IPF and consultant respiratory physician at Royal Brompton Hospital, told EP Vantage.”

 

BioCryst Hit With A HAE-Maker – Seeking Alpha, February 9, 2016

"EvaluatePharma’s consensus had been forecasting avoralstat sales in 2020 of $233m, a number that will now be deleted from all of their models…”

 

Should All These Drugs Really Be Considered ‘Orphans’? – Clinical Oncology News, February 12, 2016

"Citing data from EvaluatePharma’s 2014 Orphan Drug Report, the authors noted that the orphan drug sales market was forecast to reach $107 billion in 2015 and grow to $176 billion by 2020. (...) The median cost for orphan drugs is $98,534 per patient per year, compared with $5,153 for non-orphan drugs, they report, citing the 2014 Orphan Drug Report [EvaluatePharma, 2014]..."

 

Last week's news reviewed The Pharma Letter, February 13, 2016

“Elsewhere, commenting of French pharma major Sanofi's financial results on Tuesday (February 9), EP Vantage, the editorial arm of the Evaluate ...”

 

Looking ahead at orphan drugs' future: More breakthroughs, exploding sales BioPharmaDIVE, February 17, 2016

“Evaluate Pharma, an analysis firm, predicts worldwide orphan drug sales will grow to $178 billion, from $97 billion in 2014. This projected growth is twice as fast as that of the overall drug market, propelling orphan drugs to just over 20% of global prescription sales in 2020. In the same analysis, Evaluate Pharma calculated the average cost to patients for orphan drugs compared to non-orphans.”

 

Novartis Hopes Transcend Buy Will Relieve The Pressure On Alcon  – Seeking Alpha, February 19, 2016

“Novartis is the number one company in ophthalmic technology as judged by medical device sales, but Alcon’s sales fell 13% to $2.3bn in the fourth quarter of 2015. By 2020, it will be second fiddle to the fast-expanding Essilor International, EvaluateMedTech’s consensus data show. The company said it was looking into licensing or acquiring to improve Alcon’s performance...”

 

Alcon Acquires Transcend Medical, Expands Surgical Pipeline  – Med Device Online, February 19, 2016

“The responsibility of turning Alcon around is rather too great to hang on Transcend alone,” said analysts firm EP Vantage.”

 

IBM Grows Healthcare Cloud With $2.6bn Truven Buy Seeking Alpha, February 20, 2016

"I think it's very positive - in terms of new capital, new innovation and new ways of thinking," Andrew Schwab, managing partner of the US VC group 5AM Ventures, told EP Vantage."

 

FDA grants Breakthrough status for Novartis’ midostaurin in AML The Pharma Letter, February 20, 2016

"Midostaurin has been in trials for over a decade, and sellside consensus is for 2020 sales of only $124 million, according to EvaluatePharma."

 

Another look at last week's news The Pharma Letter, February 21, 2016

“... Rhopressa) and Ocular Therapeutix (with travoprost), on clinical trial updates that can at best only be described as mixed, commented EP Vantage, ...”

 

The top 20 drugs in 2020 -worldwide sales FiercePharma, February 22, 2016

“But for this moment in time, we present the 20 drugs expected to top the worldwide ranks in 2020, as analyzed by the market research and consulting firm EvaluatePharma.”

 

Truven: IBM's Latest Buy, Attempt to Push Watson Market Realist, February 23, 2016

“According to EP Vantage, 2016 has started off on a good foot for the medical technology industry, wherein five deals of more than $1 billion have already happened.”

 

Opdivo wins thumbs up from CHMP for two indications, in lung and kidney cancers – Seeking Alpha, February 26, 2016

“The European Commission generally accepts CHMP recommendations within 90 days but since the final OK is not yet in hand, Bristol-Myers Squibb was characteristically restrained in its reaction to the news which further advances a drug that EvaluatePharma says will reach sales of $8.4 billion by 2020.”

 

Panel Vote Could See Abbott's Stent Hopes Dissolve – Seeking Alpha, February 26, 2016

“When EP Vantage spoke to the president of Abbott Vascular, Deepak Nath, at last year's ESC meeting, he was adamant that a primary endpoint hit in Absorb III was "what's needed" to gain US approval.”

 

Raleigh's Flag receives coveted FDA Orphan Drug Designation  – The Pharma Letter, February 29, 2016

“By 2014, 468 indication designations covering 373 drugs had been approved, according to a report by EvaluatePharma, which estimates worldwide orphan drug sales to increase from $65 billion in 2010 to $176 billion in 2020”

 

Another look at last week’s news 2 – The Pharma Letter, February 29, 2016

“... to show a benefit in its Phase III Frame study in postmenopausal women with osteoporosis, commented EP Vantage, the editorial arm of the Evaluate group...”

 

 January 2016

The biggest winners--and losers--in the 2015 race for new drug approvals – Fierce Biotech, January 4, 2016 
"EvaluatePharma projects sales of the cancer drug to hit $424 million by 2019, but Japan's Eisai is hoping to reach $1 billion by 2020..."

Survey Reveals Importance of Distribution and Logistics PartnershipsLife Sciences Logistics, January 4, 2016
"A recent study by EvaluatePharma expects that by 2018, seven of the top 10 pharmaceutical drugs will be temperature-sensitive…"

The 8 most expensive drugs set to hit shelves in 2016 Washington Examiner, January 4, 2016
"The top eight new drugs treating serious illnesses, from cancer to HIV to multiple sclerosis, are projected to generate $16.6 billion in sales four years from now, after they've been on the market for a while, according Wall Street analysts at EP Vantage…"
*Also appeared on One News Now

Cell Guidance Systems raises cash to commercialise armour-plated proteinsBusiness Weekly, January 4, 2016
"According to Evaluate Pharma, the protein drug market, which was worth $154 billion in 2010, is expected to grow to $234bn by 2018…"

3 Attractive Income Stocks Whose Dividends Could DoubleMotley Fool, January 7, 2016
"Based on data from EvaluatePharma via The Wall Street Journal, we're looking at $15.7 billion in combined generic drug sales from 2014 between Teva and Allergan..."

mAbs to Watch in 2016Process Development Forum, January 10, 2016
"And there may be many more of these types of proteins on the horizon—as many as 14 are projected to hit the market in 2016, according to data compiled by EvaluatePharma, in collaboration with BioPharm International (*)…"

Key takeaways from the Shire-Baxalta deal — and the state’s new largest drugmakerBoston Business Journal, January 11, 2016
"An analysis a few months ago by EP Vantage finds that the biggest single drug over the next few years at the combined company would be Shire’s best-selling ADHD drug, Vyvanse…"

USA: UPDATE: Shire kauft BaxaltaMarkte weltweit, January 11, 2016
"Das fusionierte Unternehmen dürfte auf Platz 19 der größten Pharmakonzerne weltweit rangieren, vor bekannten Firmen wie Celgene oder Biogen, meldeten die Marktforscher von EvaluatePharma…"

Η Shire εξαγοράζει την Baxalta για $32 δισ.Euro2Day, January 11, 2016
“Η εξαγορά θα ενισχύσει τη θέση της Shire στην αγορά των θεραπειών για σπάνιες παθήσεις, η οποία αναμένεται σύμφωνα με τη συμβουλευτική EvaluatePharma να αναπτυχθεί πάνω από 60% τα επόμενα 5 χρόνια…”

Shire buys Baxalta for €29 billion to become world’s biggest drugs specialistSunday Business Post, January 11, 2016
"The acquisition of the Deerfield, Illinois-based company boosts Shire’s position in the market for rare-disease treatments, which will grow by more than 60 per cent over the next five years to $176 billion, according to market researcher EvaluatePharma. .."

Lukrative Produkte gegen seltene LeidenNeue Zurcher Zeitung, January 11, 2016
"Laut den Erwartungen der Marktforschungsfirma Evaluate Pharma verspricht das Geschäft mit Orphan Drugs branchenweit bis 2020 durchschnittlich um fast 12% pro Jahr zu expandieren. .."

Cardiovascular y VIH, áreas que perderán más patentes en 2016Diagnostics News, January 11, 2016
"De aquí a 2020 se espera el vencimiento de las patentes de fármacos cuyas ventas acumulan 259.000 millones de dólares (204.000 millones de euros aproximadamente), tal y como apuntaba el informe de 2014 publicado por la consultora Evaluate Pharma…"

Shire krallt sich Baxaltan.tv, January 11, 2016
"Das fusionierte Unternehmen dürfte an Stelle 19 der größten Pharmakonzerne weltweit rangieren, vor bekannten Firmen wie Celgene oder Biogen, erklären die Marktforscher von EvaluatePharma…"

Shire/Baxalta M&A deal: tax status proved a focal point, says expertThe Pharma Letter, January 12, 2016
Once Shire’s chief executive, Flemming Ornskov, dug in his heels he wasn’t about to let something like a 27% share price slide deter him from acquiring Baxter’s biopharmaceuticals spin-off Baxalta, comments EP Vantage, the editorial arm of the Evaluate group…"

Dublin-based Shire buys Baxalta for $32bn to become leading drugs specialistIrish Times, January 12, 2015
The acquisition of the Deerfield, Illinois-based company boosts Shire’s position in the market for rare-disease treatments, which will grow by more than 60 per cent over the next five years to $176 billion, according to market researcher EvaluatePharma…"

Yetim ilaç pazarında evlilik.. Eczaciyiz, January 12, 2016
“Piyasa araştırmacısı EvaluatePharma'ya göre söz konusu sektör, gelecek beş yıl içerisinde yüzde 60 büyüme kaydederek 176 milyar dolar düzeyine ulaşacak…”

Shire Clinches Deal for BaxaltaWall Street Journal, January 12, 2016
"Separate from tax considerations, the Shire-Baxalta deal would catapult the two midsize drug companies into the same league as Bristol-Myers Squibb Co. based on global prescription sales, according to data from EvaluatePharma, a market intelligence company…"

US pharma firm Baxalta accepts Shire's $32bn bid - Economic Times HealthWorld, January 12, 2016
"Treatments for rare diseases accounted for about $20 billion in annual sales in 2000. By 2020, those payments are expected to reach $176 billion, according to an October 2014 report by EvaluatePharma…"

Insiders' Guide To Winning In the Drug Delivery Device Market — Part 1: DesignMed Device Online January 12, 2016
"EvaluatePharma projects that biologics will represent 50 percent of the world’s top-selling drugs by 2020…"

US pharma firm Baxalta accepts Shire’s US$32b bid - Brunei Times, January 12, 2016
"Treatments for rare diseases accounted for about US$20 billion in annual sales in 2000. By 2020, those payments are expected to reach US$176 billion, according to an October 2014 report by EvaluatePharma…"

Ireland gets latest mega-corporation as Shire buys up BaxaltaIndependent.ie, January 12, 2016
"The planned acquisition boosts Dublin-based Shire's position in the market for rare-disease treatments, which will grow by more than 60pc over the next five years to $176bn, according to market researcher EvaluatePharma. .."

Farmaci: nel 2016 il lancio di dodici nuovi blockbusterSocialfarma, January 13, 2016
"Secondo il report "Pharma & Biotech 2016 Preview", pubblicato da Ep Vantage, nel 2016 sono previsti il lancio di dodici nuovi farmaci "blockbuster", l'aumento della produttività e un modesto numero di scadenze brevettuali. .."

La unión de Pfizer y Allergan venderá en fármacos 65.000 millones de euros en 2016ElGlobal.net, January 13, 2016
"La consultora Evaluate Pharma acaba de hacer pública sus previsiones sobre el comportamiento de las principales compañías farmacéuticas tendrán a lo largo de 2016, resultando que la combinación de Pfizer con Allergan, tras la fusión de ambas en noviembre pasado, liderará esta clasificación con unas ventas de 64.911 millones de euros (70.400 millones de dólares)…"

How low will they go? Mass. biotechs have shed billions this yearBoston Business Journal, January 14, 2016
"It was October 2013 that Lisa Urquhart of EvaluatePharma used the word "very" three times in telling me that she thought the biotech market was "looking very, very, very frothy at the moment…"

Los medicamentos más vendidos en 2016 - PharmaExpertise, January 14, 2016
"Según valora la consultora EvaluatePharma, el gran lanzamiento de este año será el antiviral Tenofovir Alafenamide, de Gilead, con una previsión de ventas de 3.700 millones de dólares…"

Fusion im Wachstumsmarkt Orphan Drugs: Shire kauft BaxaltaHealthcare Marketing, January 14, 2016
"Der Marktforscher Evaluate Pharma erwartet für das Marktsegment ein Wachstum von mehr als 60 Prozent auf 176 Milliarden Dollar Umsatz in den nächsten fünf Jahren…"

4 Hot MedTech Stocks for Q4 EarningsZacks, January 19, 2016
"However, an EvaluateMedTech World Preview claims that the MedTech space is positioned for impressive growth in the near term…"

Shire CEO Says Baxalta Deal Isn't About Cost Savings, TaxesBloomberg, January 15, 2016
"The market for rare disease treatments is projected to grow by more than 60 percent over the next five years to $176 billion, according to market researcher EvaluatePharma..."
*Also appeared on Bidness ETC

Farmaci, report di EP Vantage: nel 2016 in campo 12 blockbusterAbout Pharma, January 16, 2016
"Sono questi, in estrema sintesi, gli elementi principali che caratterizzeranno il mercato farmaceutico nel 2016 secondo il report"Pharma & Biotech 2016 Preview" pubblicato da EP Vantage…"

Shire übernimmt BaxaltaChemanger, January 17, 2016
"Das fusionierte Unternehmen dürfte an Stelle 19 der größten Pharmakonzerne weltweit rangieren, vor bekannten Firmen wie Celgene oder Biogen, erklären die Marktforscher von EvaluatePharma…"

Что ожидает фармацевтические компании в 2016 г.?Apteka.ua, January 18, 2016
“По прогнозам аналитической компании «Evaluate Pharma», 2016 г. будет довольно стабильным периодом для фармацевтических компаний…”

Top mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accentFierceBiotech, January 19, 2016
"But while the money flowed like never before, the number of companies enjoying the surge actually dwindled, barely beating the all-time low, the analysts add, based on numbers from Evaluate Pharma…"

Blockbuster in rampa di lancio? Notiziario Chminico Farmaceutics, January 19, 2016
"Dodici nuovi farmaci il cui lancio è atteso per il 2016 potrebbero, entro il 2020, raggiungere livelli di vendita tipici dei blockbuster: la buona notizia – per un mercato farmaceutico sempre più in cerca di novità e fatturati importanti – viene dal recente report "Pharma & Biotech 2016 Preview" pubblicato da EP Vantage…"

Pfizer liderará el 'ranking' global de la industria farmacéutica en 2016Farmavenix, January 19, 2016
"Se alejará así notablemente de su rival Novartis (con un pronóstico de 44.500 millones en ventas), pero aun sin Allergan, Pfizer por sí sola aventajaría a la suiza gracias a unas previsiones de facturación situadas en los 48.000 millones de dólares según la consultora Evaluate, recogidas en su informe EP Vantage 2016 Preview..."

4 Hot MedTech Stocks for Q4 EarningsZacks, January 19, 2016
"However, an EvaluateMedTech World Preview claims that the MedTech space is positioned for impressive growth in the near term…"

Dispositivi medici, la crescita continuaFare, January 19, 2016
"Si tratta di un comparto innovativo, dinamico e in crescita un po’ ovunque: Gli analisti stimano che il settore dei DM, a livello mondiale, crescerà ad un tasso del 5% (CAGR) tra il 2013 ed il 2020, raggiungendo nel 2020 un fatturato complessivo di 514 miliardi di dollari (EvaluateMedTech, 2014)…"

La industria busca salidas de cara a cinco años con importantes pérdidas de patentesElGlobal, January 20, 2016
"Según el informe 'EP Vantage 2016 Preview', publicado por la consultora internacional EvaluatePharma, compañías como Abbvie, Roche, AstraZeneca, Johnson&Johnson o GSK, sufrirán pérdidas de patentes en los próximos cinco años que afectarán a sus ventas…"

Global Pharma Industry in 2016Smart Cube, January 25, 2016
"Further, according to the EvaluatePharma World Preview 2015, Outlook to 2020 report, by 2020, 9 out of the 10 best-selling drugs (by revenue) in the US will be specialty drugs, compared with 7 in 2014…"

2015 Medtech Approvals Highest in a DecadeMedical Device & Diagnostics Industry, January 26, 2016
"In 2015, the agency granted a total of 51 first-time PMAs and humanitarian device exemptions, according to Evaluate Medtech and EP Vantage, the publishing arm of Evaluate, a market intelligence firm…"

2015 Medtech Approvals Highest in a Decade – Medical Device and Diagnostics Industry, January 27, 2016 
"In 2015, the agency granted a total of 51 first-time PMAs and humanitarian device exemptions, according to Evaluate Medtech and EP Vantage, the ..."

The top 10 (possible) blockbusters that (might) launch this yearFierceBiotech, January 28, 2016
"EvaluatePharma gathered the consensus numbers on projected 2020 sales for the drugs being watched for a 2016 launch and came up with separate tallies on the top 10 biologics and top 10 small molecules..."

Merck goes toe-to-toe with Gilead's hep C goliath, flags discount with blockbuster OKFierceBiotech, January 28, 2016
"EvaluatePharma, meanwhile, noted recently that Merck's combo ranks as the biggest likely seller among new small molecules to undergo an FDA review this year…"

Tendances Bourse : Le boom des biotherapiesLa Montagne.fr, January 31, 2016
"Selon le cabinet de recherche Evaluate Pharma, les ventes de biothérapies se sont envolées de 78 milliards de dollars en 2006 à 179 milliards en 2014, et elles devraient flirter avec les 300 milliards en 2020, pour représenter près d'un tiers du marché pharmaceutique mondial…"

Archive

 Evaluate Buzz 2015

 Evaluate Buzz 2014

 Evaluate Buzz 2013

 Evaluate Buzz 2012

 Evaluate Buzz 2011